```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:ssspta1626gms

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1         Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2         "Ask CAS" for self-help around the clock
 NEWS  3  JAN 27  Source of Registration (SR) information in REGISTRY updated
                 and searchable
 NEWS  4  JAN 27  A new search aid, the Company Name Thesaurus, available in
                 CA/CAplus
 NEWS  5  FEB 05  German (DE) application and patent publication number format
                 changes
 NEWS  6  MAR 03  MEDLINE and LMEDLINE reloaded
 NEWS  7  MAR 03  MEDLINE file segment of TOXCENTER reloaded
 NEWS  8  MAR 03  FRANCEPAT now available on STN
 NEWS  9  MAR 29  Pharmaceutical Substances (PS) now available on STN
 NEWS 10  MAR 29  WPIFV now available on STN
 NEWS 11  MAR 29  New monthly current-awareness alert (SDI) frequency in RAPRA
 NEWS 12  APR 26  PROMT: New display field available
 NEWS 13  APR 26  IFIPAT/IFIUDB/IFICDB: New super search and display field
                 available
 NEWS 14  APR 26  LITALERT now available on STN
 NEWS 15  APR 27  NLDB: New search and display fields available
 NEWS 16  May 10  PROUSDDR now available on STN
 NEWS 17  May 19  PROUSDDR: One FREE connect hour, per account, in both May
                 and June 2004
 NEWS 18  May 12  EXTEND option available in structure searching
 NEWS 19  May 12  Polymer links for the POLYLINK command completed in REGISTRY
 NEWS 20  May 17  FRFULL now available on STN

 NEWS EXPRESS  MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.
  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:12:21 ON 25 MAY 2004

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files.  For example, the EXPAND
command can only be used to look at the index in a file which has an
index.  Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of
commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS                                  SINCE FILE       TOTAL
                                                           ENTRY     SESSION
FULL ESTIMATED COST                                         0.21        0.21

FILE 'REGISTRY' ENTERED AT 12:12:45 ON 25 MAY 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   24 MAY 2004  HIGHEST RN 685504-43-2
DICTIONARY FILE UPDATES:  24 MAY 2004  HIGHEST RN 685504-43-2

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\10679604.str
```





```
chain nodes :
6  7  14  15  16  17  18  19  20
ring nodes :
```

```
1  2  3  4  5  8  9  10  11  12  13
chain bonds :
2-20  4-6  6-7  7-8  11-14  14-15  15-16  16-17  16-19  17-18
ring bonds :
1-2  1-5  2-3  3-4  4-5  8-9  8-13  9-10  10-11  11-12  12-13
exact/norm bonds :
1-2  1-5  2-3  2-20  3-4  4-5  7-8
exact bonds :
4-6  6-7  11-14  14-15  15-16  17-18
normalized bonds :
8-9  8-13  9-10  10-11  11-12  12-13  16-17  16-19
isolated ring systems :
containing 1 : 8 :


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:CLASS  7:CLASS  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:Atom  14:CLASS  15:CLASS  16:CLASS  17:CLASS  18:CLASS
19:CLASS  20:Atom



L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR
```



```
Structure attributes must be viewed using STN Express query preparation.


=> s l1
SAMPLE SEARCH INITIATED 12:13:02 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     10 TO ITERATE

100.0% PROCESSED      10 ITERATIONS                           3 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:           11 TO      389
PROJECTED ANSWERS:               3 TO      163

L2            3 SEA SSS SAM L1

=> s l1 sss full
```

```
FULL SEARCH INITIATED 12:13:09 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    221 TO ITERATE

100.0% PROCESSED     221 ITERATIONS                             83 ANSWERS
SEARCH TIME: 00.00.01

L3            83 SEA SSS FUL L1

=> FIL CAPLUS
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                       155.42     155.63

FILE 'CAPLUS' ENTERED AT 12:13:19 ON 25 MAY 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 25 May 2004  VOL 140 ISS 22
FILE LAST UPDATED: 24 May 2004  (20040524/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.


=> s l3
L4             4 L3

=> d l4 ibib abs hitstr tot

L4   ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER:         2004:308424  CAPLUS
DOCUMENT NUMBER:          140:321346
TITLE:                    Preparation of chiral oxazole-arylpropionic acid
                          derivatives and their use as PPARα and
                          PPARγ agonists for disorders like type II
                          diabetes
INVENTOR(S):              Binggeli, Alfred; Boehringer, Markus; Grether, Uwe;
                          Hilpert, Hans; Hirth, Georges; Maerki, Hans-Peter;
                          Meyer, Markus; Mohr, Peter; Ricklin, Fabienne
PATENT ASSIGNEE(S):       F. Hoffmann-La Roche A.-G., Switz.
SOURCE:                   PCT Int. Appl., 108 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.        KIND  DATE              APPLICATION NO.  DATE
```

Inventor

```
    ---------------  ----  --------       ---------------  --------
    WO 2004031162     A1    20040415       WO 2003-EP11030   20031006
        W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
            GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
            LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
            OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
            TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
            CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
            NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
            GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.:                     EP 2002-22286    A  20021007
GI
```



I



II

AB The present invention relates to chiral oxazole-arylpropionic acid derivs. (shown as I; variables defined below; e.g. II) and pharmaceutically acceptable salts and esters thereof. The compds. are useful for the treatment and/or prevention of diseases, which are modulated by PPARα and/or PPARγ agonists as e.g. type II diabetes. For I: R1 is aryl or heteroaryl; R2 is H, lower-alkyl, or fluoro-lower-alkyl; R3 and R4 = H, hydroxy, halogen, lower-alkyl, fluoro-lower-alkyl, hydroxy-lower-alkyl, lower-alkoxy-lower-alkyl, lower-alkoxy, fluoro-lower-alkoxy, hydroxy-lower-alkoxy, lower-alkoxy-lower-alkoxy, or lower-alkenyl, wherein at least one of R3 and R4 is not H; R5 is lower-alkoxy, fluoro-lower-alkoxy, lower-alkenyloxy, fluoro-lower-alkenyloxy, aryloxy, aryl-lower-alkoxy, or arylfluoro-lower-alkoxy; R6 is H or lower-alkyl; n is 1. EC50 and IC50 values for 10 examples of I towards PPARα and PPARγ are tabulated, e.g. IC50 = 30 and 58 nmol/L for PPARα and PPARγ, resp. for II. A method of preparation involving removing a protective ester radical (R6 = protective group) is claimed. Approx. 50 examples prepns. of I are included. For example, II was prepared in 4 steps starting with cyclization of diacetyl monooxime with 4-isopropoxybenzaldehyde to give 2-(4-isopropoxyphenyl)-4,5-

dimethyloxazole 3-oxide hydrochloride, which was converted with POCl3 to 4-chloromethyl-2-(4-isopropoxyphenyl)-5-methyloxazole, which was coupled to (2S)-2-ethoxy-3-(4-hydroxy-2-methylphenyl)propionic acid Me ester to give (S)-2-ethoxy-3-[4-[2-(4-isopropoxyphenyl)-5-methyloxazol-4-ylmethoxy]-2-methylphenyl]propionic acid Me ester, which was hydrolyzed by LiOH to the acid.

IT **678164-68-6P**, (S)-3-[4-[2-(3,5-Dichlorophenyl)-5-methyloxazol-4-ylmethoxy]-2-methylphenyl]-2-ethoxypropionic acid **678164-75-5P**, (S)-2-Ethoxy-3-[2-methyl-4-[5-methyl-2-(2-trifluoromethylphenyl)oxazol-4-ylmethoxy]phenyl]propionic acid **678164-79-9P**, (S)-2-Ethoxy-3-[2-methyl-4-[5-methyl-2-(3-trifluoromethylphenyl)oxazol-4-ylmethoxy]phenyl]propionic acid **678164-82-4P**, (S)-2-Ethoxy-3-[4-[2-(4-fluorophenyl)-5-methyloxazol-4-ylmethoxy]-2-methylphenyl]propionic acid **678164-85-7P**, (S)-2-Ethoxy-3-[2-methyl-4-[5-methyl-2-(4-trifluoromethylphenyl)oxazol-4-ylmethoxy]phenyl]propionic acid **678164-88-0P**, (S)-2-Ethoxy-3-[4-[2-(4-isopropylphenyl)-5-methyloxazol-4-ylmethoxy]-2-methylphenyl]propionic acid **678164-91-5P**, (S)-2-Ethoxy-3-[2-methyl-4-[5-methyl-2-(3,4,5-trimethoxyphenyl)oxazol-4-ylmethoxy]phenyl]propionic acid **678165-10-1P**, (S)-3-[4-[2-(2-Chlorophenyl)oxazol-4-ylmethoxy]-2-methylphenyl]-2-ethoxypropionic acid **678165-17-8P**, (S)-2-Ethoxy-3-[4-[2-(3-methoxyphenyl)oxazol-4-ylmethoxy]-2-methylphenyl]propionic acid **678165-21-4P**, (S)-3-[4-[2-(4-tert-Butylphenyl)-5-methyloxazol-4-ylmethoxy]-2-ethoxyphenyl]-2-ethoxypropionic acid **678165-24-7P**, (S)-2-Ethoxy-3-[2-ethoxy-4-[2-(4-isopropoxyphenyl)-5-methyloxazol-4-ylmethoxy]phenyl]propionic acid **678165-26-9P**, (S)-3-[4-[2-(3-Chlorophenyl)-5-methyloxazol-4-ylmethoxy]-2-ethoxyphenyl]-2-ethoxypropionic acid **678165-42-9P**, (S)-3-[4-[2-(4-tert-Butylphenyl)-5-methyloxazol-4-ylmethoxy]-2-isopropoxyphenyl]-2-ethoxypropionic acid

RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of chiral oxazole-arylpropionic acid derivs. and their use as PPARα and PPARγ agonists for disorders like type II diabetes)

RN 678164-68-6 CAPLUS

CN Benzenepropanoic acid, 4-[[2-(3,5-dichlorophenyl)-5-methyl-4-oxazolyl]methoxy]-α-ethoxy-2-methyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 678164-75-5 CAPLUS

CN Benzenepropanoic acid, α-ethoxy-2-methyl-4-[[5-methyl-2-[2-(trifluoromethyl)phenyl]-4-oxazolyl]methoxy]-, (αS)- (9CI) (CA

INDEX NAME)

Absolute stereochemistry.



RN 678164-79-9 CAPLUS
CN Benzenepropanoic acid, α-ethoxy-2-methyl-4-[[5-methyl-2-[3-(trifluoromethyl)phenyl]-4-oxazolyl]methoxy]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 678164-82-4 CAPLUS
CN Benzenepropanoic acid, α-ethoxy-4-[[2-(4-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]-2-methyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 678164-85-7 CAPLUS
CN Benzenepropanoic acid, α-ethoxy-2-methyl-4-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]methoxy]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 678164-88-0 CAPLUS
CN Benzenepropanoic acid, α-ethoxy-2-methyl-4-[[5-methyl-2-[4-(1-methylethyl)phenyl]-4-oxazolyl]methoxy]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 678164-91-5 CAPLUS
CN Benzenepropanoic acid, α-ethoxy-2-methyl-4-[[5-methyl-2-(3,4,5-trimethoxyphenyl)-4-oxazolyl]methoxy]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 678165-10-1 CAPLUS
CN Benzenepropanoic acid, 4-[[2-(2-chlorophenyl)-4-oxazolyl]methoxy]-α-ethoxy-2-methyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 678165-17-8 CAPLUS
CN Benzenepropanoic acid, α-ethoxy-4-[[2-(3-methoxyphenyl)-4-oxazolyl]methoxy]-2-methyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 678165-21-4 CAPLUS
CN Benzenepropanoic acid, 4-[[2-[4-(1,1-dimethylethyl)phenyl]-5-methyl-4-oxazolyl]methoxy]-α,2-diethoxy-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 678165-24-7 CAPLUS
CN Benzenepropanoic acid, α,2-diethoxy-4-[[5-methyl-2-[4-(1-methylethoxy)phenyl]-4-oxazolyl]methoxy]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 678165-26-9 CAPLUS

CN Benzenepropanoic acid, 4-[[2-(3-chlorophenyl)-5-methyl-4-oxazolyl]methoxy]-α,2-diethoxy-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 678165-42-9 CAPLUS

CN Benzenepropanoic acid, 4-[[2-[4-(1,1-dimethylethyl)phenyl]-5-methyl-4-oxazolyl]methoxy]-α-ethoxy-2-(1-methylethoxy)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **678163-77-4P**, (S)-2-Ethoxy-3-[2-methyl-4-[5-methyl-2-(o-tolyl)oxazol-4-ylmethoxy]phenyl]propionic acid **678163-86-5P**, (S)-2-Ethoxy-3-[4-[2-(4-isopropoxyphenyl)-5-methyloxazol-4-ylmethoxy]-2-methylphenyl]propionic acid **678163-88-7P**, (S)-2-Ethoxy-3-[2-methyl-4-(5-methyl-2-phenyloxazol-4-ylmethoxy)phenyl]propionic acid **678163-92-3P**, (S)-3-[4-[2-(3,5-Dimethoxyphenyl)-5-methyloxazol-4-ylmethoxy]-2-methylphenyl]-2-ethoxypropionic acid **678163-95-6P**,

(S)-2-Ethoxy-3-[4-[2-(4-fluoro-3-methylphenyl)-5-methyloxazol-4-ylmethoxy]-
2-methylphenyl]propionic acid **678163-97-8P**, (S)-2-Ethoxy-3-[4-[2-
(2-fluorophenyl)-5-methyloxazol-4-ylmethoxy]-2-methylphenyl]propionic acid
678164-04-0P, (S)-2-Ethoxy-3-[2-ethyl-4-(5-methyl-2-phenyloxazol-4-
ylmethoxy)phenyl]propionic acid **678164-06-2P**,
(S)-2-Ethoxy-3-[2-ethyl-4-[2-(4-fluoro-3-methylphenyl)-5-methyloxazol-4-
ylmethoxy]phenyl]propionic acid **678164-08-4P**,
(S)-2-Ethoxy-3-[2-ethyl-4-[2-(2-fluorophenyl)-5-methyloxazol-4-
ylmethoxy]phenyl]propionic acid **678164-10-8P**,
(S)-2-Ethoxy-3-[2-ethyl-4-[5-methyl-2-(o-tolyl)oxazol-4-
ylmethoxy]phenyl]propionic acid **678164-12-0P**,
(S)-2-Ethoxy-3-[2-ethyl-4-[2-(4-isopropoxyphenyl)-5-methyloxazol-4-
ylmethoxy]phenyl]propionic acid **678164-14-2P**,
(S)-2-Ethoxy-3-[2-fluoro-4-(5-methyl-2-phenyloxazol-4-
ylmethoxy)phenyl]propionic acid **678164-16-4P**,
(S)-2-Ethoxy-3-[2-fluoro-4-[2-(2-fluorophenyl)-5-methyloxazol-4-
ylmethoxy]phenyl]propionic acid **678164-18-6P**,
(S)-3-[2-Chloro-4-(5-methyl-2-phenyloxazol-4-ylmethoxy)phenyl]-2-
ethoxypropionic acid **678164-21-1P**, (S)-3-[2-Chloro-4-[2-(4-
fluoro-3-methylphenyl)-5-methyloxazol-4-ylmethoxy]phenyl]-2-
ethoxypropionic acid **678164-23-3P**, (S)-3-[2-Chloro-4-[2-(4-
isopropoxyphenyl)-5-methyloxazol-4-ylmethoxy]phenyl]-2-ethoxypropionic
acid **678164-25-5P**, (S)-3-[2-Chloro-4-[2-(2-fluorophenyl)-5-
methyloxazol-4-ylmethoxy]phenyl]-2-ethoxypropionic acid
678164-27-7P, (S)-3-[2-Chloro-4-[5-methyl-2-(o-tolyl)oxazol-4-
ylmethoxy]phenyl]-2-ethoxypropionic acid **678164-29-9P**,
(S)-3-[2-Chloro-4-[2-(2-methoxyphenyl)-5-methyloxazol-4-ylmethoxy]phenyl]-
2-ethoxypropionic acid **678164-37-9P**, (S)-2-Ethoxy-3-[4-(5-methyl-
2-phenyloxazol-4-ylmethoxy)-2-trifluoromethylphenyl]propionic acid
678164-39-1P, (S)-2-Ethoxy-3-[4-[2-(2-fluorophenyl)-5-methyloxazol-
4-ylmethoxy]-2-trifluoromethylphenyl]propionic acid **678164-48-2P**
, (S)-2-Ethoxy-3-[2-methoxy-4-(5-methyl-2-phenyloxazol-4-
ylmethoxy)phenyl]propionic acid **678164-50-6P**,
(S)-2-Ethoxy-3-[4-[2-(4-isopropylphenyl)-5-methyloxazol-4-ylmethoxy]-2-
methoxyphenyl]propionic acid **678164-52-8P**, (S)-2-Ethoxy-3-[4-[2-
(4-fluoro-3-methylphenyl)-5-methyloxazol-4-ylmethoxy]-2-
methoxyphenyl]propionic acid **678164-54-0P**, (S)-2-Ethoxy-3-[4-[2-
(4-isopropoxyphenyl)-5-methyloxazol-4-ylmethoxy]-2-methoxyphenyl]propionic
acid **678164-56-2P**, (S)-3-[4-[2-(3-Chlorophenyl)-5-methyloxazol-4-
ylmethoxy]-2-methoxyphenyl]-2-ethoxypropionic acid **678164-58-4P**,
(S)-3-[2,6-Dimethyl-4-(5-methyl-2-phenyloxazol-4-ylmethoxy)phenyl]-2-
ethoxypropionic acid **678164-60-8P**, (S)-2-Ethoxy-3-[4-[[2-(4-
isopropoxyphenyl)-5-methyloxazol-4-yl]methoxy]-2,6-
dimethylphenyl]propionic acid **678164-62-0P**, (S)-2-Ethoxy-3-[4-[2-
(4-isopropylphenyl)-5-methyloxazol-4-ylmethoxy]-2,6-
dimethylphenyl]propionic acid **678164-64-2P**, (S)-3-[4-[2-(3-
Chlorophenyl)-5-methyloxazol-4-ylmethoxy]-2,6-dimethylphenyl]-2-
ethoxypropionic acid **678164-66-4P**, (S)-2-Ethoxy-3-[4-[2-(4-
fluoro-3-methylphenyl)-5-methyloxazol-4-ylmethoxy]-2,6-
dimethylphenyl]propionic acid **678164-71-1P**, (S)-3-[4-[2-(3,5-
Dimethylphenyl)-5-methyloxazol-4-ylmethoxy]-2-methylphenyl]-2-
ethoxypropionic acid **678165-04-3P**, (S)-2-Ethoxy-3-[2-methyl-4-(2-
phenyloxazol-4-ylmethoxy)phenyl]propionic acid **678165-48-5P**,
(S)-2-Ethoxy-3-[2-fluoro-4-[5-methyl-2-(o-tolyl)oxazol-4-
ylmethoxy]phenyl]propionic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(drug candidate; preparation of chiral oxazole-arylpropionic acid derivs.
and their use as PPARα and PPARγ agonists for disorders

like type II diabetes)

RN 678163-77-4 CAPLUS

CN Benzenepropanoic acid, α-ethoxy-2-methyl-4-[[5-methyl-2-(2-methylphenyl)-4-oxazolyl]methoxy]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 678163-86-5 CAPLUS

CN Benzenepropanoic acid, α-ethoxy-2-methyl-4-[[5-methyl-2-[4-(1-methylethoxy)phenyl]-4-oxazolyl]methoxy]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 678163-88-7 CAPLUS

CN Benzenepropanoic acid, α-ethoxy-2-methyl-4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 678163-92-3 CAPLUS

CN Benzenepropanoic acid, 4-[[2-(3,5-dimethoxyphenyl)-5-methyl-4-oxazolyl]methoxy]-α-ethoxy-2-methyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 678163-95-6 CAPLUS
CN Benzenepropanoic acid, α-ethoxy-4-[[2-(4-fluoro-3-methylphenyl)-5-methyl-4-oxazolyl]methoxy]-2-methyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 678163-97-8 CAPLUS
CN Benzenepropanoic acid, α-ethoxy-4-[[2-(2-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]-2-methyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 678164-04-0 CAPLUS
CN Benzenepropanoic acid, α-ethoxy-2-ethyl-4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 678164-06-2 CAPLUS
CN Benzenepropanoic acid, α-ethoxy-2-ethyl-4-[[2-(4-fluoro-3-methylphenyl)-5-methyl-4-oxazolyl]methoxy]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 678164-08-4 CAPLUS
CN Benzenepropanoic acid, α-ethoxy-2-ethyl-4-[[2-(2-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 678164-10-8 CAPLUS
CN Benzenepropanoic acid, α-ethoxy-2-ethyl-4-[[5-methyl-2-(2-methylphenyl)-4-oxazolyl]methoxy]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 678164-12-0 CAPLUS
CN Benzenepropanoic acid, α-ethoxy-2-ethyl-4-[[5-methyl-2-[4-(1-methylethoxy)phenyl]-4-oxazolyl]methoxy]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 678164-14-2 CAPLUS
CN Benzenepropanoic acid, α-ethoxy-2-fluoro-4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 678164-16-4 CAPLUS
CN Benzenepropanoic acid, α-ethoxy-2-fluoro-4-[[2-(2-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 678164-18-6 CAPLUS
CN Benzenepropanoic acid, 2-chloro-α-ethoxy-4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 678164-21-1 CAPLUS
CN Benzenepropanoic acid, 2-chloro-α-ethoxy-4-[[2-(4-fluoro-3-methylphenyl)-5-methyl-4-oxazolyl]methoxy]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 678164-23-3 CAPLUS
CN Benzenepropanoic acid, 2-chloro-α-ethoxy-4-[[5-methyl-2-[4-(1-methylethoxy)phenyl]-4-oxazolyl]methoxy]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 678164-25-5 CAPLUS
CN Benzenepropanoic acid, 2-chloro-α-ethoxy-4-[[2-(2-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 678164-27-7 CAPLUS
CN Benzenepropanoic acid, 2-chloro-α-ethoxy-4-[[5-methyl-2-(2-methylphenyl)-4-oxazolyl]methoxy]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 678164-29-9 CAPLUS
CN Benzenepropanoic acid, 2-chloro-α-ethoxy-4-[[2-(2-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 678164-37-9 CAPLUS
CN Benzenepropanoic acid, α-ethoxy-4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]-2-(trifluoromethyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 678164-39-1 CAPLUS
CN Benzenepropanoic acid, α-ethoxy-4-[[2-(2-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]-2-(trifluoromethyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 678164-48-2 CAPLUS
CN Benzenepropanoic acid, α-ethoxy-2-methoxy-4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 678164-50-6 CAPLUS
CN Benzenepropanoic acid, α-ethoxy-2-methoxy-4-[[5-methyl-2-[4-(1-methylethyl)phenyl]-4-oxazolyl]methoxy]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 678164-52-8 CAPLUS
CN Benzenepropanoic acid, α-ethoxy-4-[[2-(4-fluoro-3-methylphenyl)-5-methyl-4-oxazolyl]methoxy]-2-methoxy-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 678164-54-0 CAPLUS
CN Benzenepropanoic acid, α-ethoxy-2-methoxy-4-[[5-methyl-2-[4-(1-methylethoxy)phenyl]-4-oxazolyl]methoxy]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 678164-56-2 CAPLUS
CN Benzenepropanoic acid, 4-[[2-(3-chlorophenyl)-5-methyl-4-oxazolyl]methoxy]-α-ethoxy-2-methoxy-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 678164-58-4 CAPLUS
CN Benzenepropanoic acid, α-ethoxy-2,6-dimethyl-4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 678164-60-8 CAPLUS
CN Benzenepropanoic acid, α-ethoxy-2,6-dimethyl-4-[[5-methyl-2-[4-(1-methylethoxy)phenyl]-4-oxazolyl]methoxy]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 678164-62-0 CAPLUS

CN Benzenepropanoic acid, α-ethoxy-2,6-dimethyl-4-[[5-methyl-2-[4-(1-methylethyl)phenyl]-4-oxazolyl]methoxy]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 678164-64-2 CAPLUS

CN Benzenepropanoic acid, 4-[[2-(3-chlorophenyl)-5-methyl-4-oxazolyl]methoxy]-α-ethoxy-2,6-dimethyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 678164-66-4 CAPLUS

CN Benzenepropanoic acid, α-ethoxy-4-[[2-(4-fluoro-3-methylphenyl)-5-methyl-4-oxazolyl]methoxy]-2,6-dimethyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 678164-71-1 CAPLUS
CN Benzenepropanoic acid, 4-[[2-(3,5-dimethylphenyl)-5-methyl-4-oxazolyl]methoxy]-α-ethoxy-2-methyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 678165-04-3 CAPLUS
CN Benzenepropanoic acid, α-ethoxy-2-methyl-4-[(2-phenyl-4-oxazolyl)methoxy]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 678165-48-5 CAPLUS
CN Benzenepropanoic acid, α-ethoxy-2-fluoro-4-[[5-methyl-2-(2-methylphenyl)-4-oxazolyl]methoxy]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **678164-69-7P**, 3-[4-[2-(3,5-Dichlorophenyl)-5-methyloxazol-4-ylmethoxy]-2-methylphenyl]-2-ethoxypropionic acid **678164-72-2P**, 3-[4-[2-(3,5-Dimethylphenyl)-5-methyloxazol-4-ylmethoxy]-2-methylphenyl]-2-ethoxypropionic acid **678164-76-6P**, 2-Ethoxy-3-[2-methyl-4-[5-methyl-2-(2-trifluoromethylphenyl)oxazol-4-ylmethoxy]phenyl]propionic acid **678164-80-2P**, 2-Ethoxy-3-[2-methyl-4-[5-methyl-2-(3-trifluoromethylphenyl)oxazol-4-ylmethoxy]phenyl]propionic acid **678164-83-5P**, 2-Ethoxy-3-[4-[2-(4-fluorophenyl)-5-methyloxazol-4-ylmethoxy]-2-methylphenyl]propionic acid **678164-86-8P**, 2-Ethoxy-3-[2-methyl-4-[5-methyl-2-(4-trifluoromethylphenyl)oxazol-4-ylmethoxy]phenyl]propionic acid **678164-89-1P**, 2-Ethoxy-3-[4-[2-(4-isopropylphenyl)-5-methyloxazol-4-ylmethoxy]-2-methylphenyl]propionic acid **678164-92-6P**, 2-Ethoxy-3-[2-methyl-4-[5-methyl-2-(3,4,5-trimethoxyphenyl)oxazol-4-ylmethoxy]phenyl]propionic acid **678165-12-3P**, 3-[4-[2-(2-Chlorophenyl)oxazol-4-ylmethoxy]-2-methylphenyl]-2-ethoxypropionic acid **678165-19-0P**, 2-Ethoxy-3-[4-[2-(3-methoxyphenyl)oxazol-4-ylmethoxy]-2-methylphenyl]propionic acid **678165-23-6P**, 3-[4-[2-(4-tert-Butylphenyl)-5-methyloxazol-4-ylmethoxy]-2-ethoxyphenyl]-2-ethoxypropionic acid **678165-25-8P**, 2-Ethoxy-3-[2-ethoxy-4-[2-(4-isopropoxyphenyl)-5-methyloxazol-4-ylmethoxy]phenyl]propionic acid **678165-28-1P**, 3-[4-[2-(3-Chlorophenyl)-5-methyloxazol-4-ylmethoxy]-2-ethoxyphenyl]-2-ethoxypropionic acid **678165-44-1P**, 3-[4-[2-(4-tert-Butylphenyl)-5-methyloxazol-4-ylmethoxy]-2-isopropoxyphenyl]-2-ethoxypropionic acid

RL: PEP (Physical, engineering or chemical process); PYP (Physical process); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); PROC (Process); RACT (Reactant or reagent)

(resolution; preparation of chiral oxazole-arylpropionic acid derivs. and their use as PPARα and PPARγ agonists for disorders like type II diabetes)

RN 678164-69-7 CAPLUS

CN Benzenepropanoic acid, 4-[[2-(3,5-dichlorophenyl)-5-methyl-4-oxazolyl]methoxy]-α-ethoxy-2-methyl- (9CI) (CA INDEX NAME)



RN 678164-72-2 CAPLUS
CN Benzenepropanoic acid, 4-[[2-(3,5-dimethylphenyl)-5-methyl-4-oxazolyl]methoxy]-α-ethoxy-2-methyl- (9CI) (CA INDEX NAME)



RN 678164-76-6 CAPLUS
CN Benzenepropanoic acid, α-ethoxy-2-methyl-4-[[5-methyl-2-[2-(trifluoromethyl)phenyl]-4-oxazolyl]methoxy]- (9CI) (CA INDEX NAME)



RN 678164-80-2 CAPLUS
CN Benzenepropanoic acid, α-ethoxy-2-methyl-4-[[5-methyl-2-[3-(trifluoromethyl)phenyl]-4-oxazolyl]methoxy]- (9CI) (CA INDEX NAME)



RN 678164-83-5 CAPLUS
CN Benzenepropanoic acid, α-ethoxy-4-[[2-(4-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 678164-86-8 CAPLUS
CN Benzenepropanoic acid, α-ethoxy-2-methyl-4-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]methoxy]- (9CI) (CA INDEX NAME)



RN 678164-89-1 CAPLUS
CN Benzenepropanoic acid, α-ethoxy-2-methyl-4-[[5-methyl-2-[4-(1-methylethyl)phenyl]-4-oxazolyl]methoxy]- (9CI) (CA INDEX NAME)



RN 678164-92-6 CAPLUS
CN Benzenepropanoic acid, α-ethoxy-2-methyl-4-[[5-methyl-2-(3,4,5-trimethoxyphenyl)-4-oxazolyl]methoxy]- (9CI) (CA INDEX NAME)



RN 678165-12-3 CAPLUS
CN Benzenepropanoic acid, 4-[[2-(2-chlorophenyl)-4-oxazolyl]methoxy]-α-ethoxy-2-methyl- (9CI) (CA INDEX NAME)



RN 678165-19-0 CAPLUS
CN Benzenepropanoic acid, α-ethoxy-4-[[2-(3-methoxyphenyl)-4-oxazolyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 678165-23-6 CAPLUS
CN Benzenepropanoic acid, 4-[[2-[4-(1,1-dimethylethyl)phenyl]-5-methyl-4-oxazolyl]methoxy]-α,2-diethoxy- (9CI) (CA INDEX NAME)



RN 678165-25-8 CAPLUS
CN Benzenepropanoic acid, α,2-diethoxy-4-[[5-methyl-2-[4-(1-methylethoxy)phenyl]-4-oxazolyl]methoxy]- (9CI) (CA INDEX NAME)



RN 678165-28-1 CAPLUS
CN Benzenepropanoic acid, 4-[[2-(3-chlorophenyl)-5-methyl-4-oxazolyl]methoxy]-α,2-diethoxy- (9CI) (CA INDEX NAME)



RN 678165-44-1 CAPLUS
CN Benzenepropanoic acid, 4-[[2-[4-(1,1-dimethylethyl)phenyl]-5-methyl-4-oxazolyl]methoxy]-α-ethoxy-2-(1-methylethoxy)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:633643 CAPLUS
DOCUMENT NUMBER: 139:180343
TITLE: Preparation of aromatic amino acid derivatives as anticancer agents
INVENTOR(S): Endo, Hitoshi; Kanai, Yoshikatsu; Tsujihara, Kenji; Saito, Kunio
PATENT ASSIGNEE(S): Japan
SOURCE: PCT Int. Appl., 124 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003066574	A1	20030814	WO 2003-JP1081	20030203

W: AE, AG, AL, ~~AM, AT~~, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD,
RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: JP 2002-31216 A 20020207
OTHER SOURCE(S): MARPAT 139:180343
GI



I

AB Aromatic amino acid derivs. represented by the following general formula (I) or pharmacol. acceptable salts thereof [wherein R1 represents hydrogen or an amino-protecting group; R2 represents hydrogen, alkylaralkyl or aryl; R3 represents (1) halogeno, (2) aroylamino, (3) Ph substituted by lower alkyl, Ph, phenoxy, etc., (4) naphthyl or tetrahydronaphthyl optionally substituted by hydroxy, lower alkoxy or di(lower alkyl)amino, (5) an N-, O- and/or S-containing unsatd. monocyclic heterocycle group substituted by lower alkyl, Ph, naphthyl or tetrahydroquinolyl, or (6) an N-, O- and/or S-containing fused heterocycle group, which may be unsatd. or partly saturated, optionally substituted by oxo, carboxy, amino, lower alkyl, etc.; X represents halogeno, alkyl or alkoxy; Y represents oxygen or nitrogen; p is 0 or 1; m is 0, 1 or 2; and n is an integer of from 0 to 5] are prepared These compds. inhibit a transporter (LAT1) of essential amino acids which are one of the main nutrients for cancer cells and induce depletion of the essential amino acids in the cancer cells, thereby inhibit the proliferation of the cancer cells. Thus, 0.2 mL pyridine was added to a suspension of N-trifluoroacetyl-3-hydroxy-L-phenylalanine Et ester 159, 2-naphthaleneboronic acid 186, mol. sieve 4A 204, and Cu(OAc)2 153 mg in 7 mL CH2Cl2, stirred at room temperature for 16 h in air to give, after workup and silica gel chromatog., 89% N-trifluoroacetyl-3-(2-naphthyloxy)-L-phenylalanine Et ester (II). 0.5 N aqueous NaOH was added to a solution of II (94 mg) in 2 mL THF at 5°, stirred at 5° for 69 h, acidified with 1 N aqueous HCl to pH 3-4, and filtered to give 78% 3-(2-naphthyloxy)-L-phenylalanine (III). In an assay for a LAT1 inhibitory activity, III and 3-[3-(6-dimethylaminopyridyl)phenoxy]-L-phenylalanine in vitro showed IC50 of 0.1 and 0.01 μg/mL, resp., for inhibiting the uptake of [14C]-L-tyrosine by human prostatic cancer T24 cells.

IT **579524-01-9P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aromatic amino acid derivs. as anticancer agents for inhibiting proliferation of cancer cells by inhibiting essential amino acid transporter (LAT1))

RN 579524-01-9 CAPLUS

CN L-Tyrosine, 3,5-dichloro-O-[(2-phenyl-4-oxazolyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



```
REFERENCE COUNT:          20    THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS
                                RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4   ANSWER 3 OF 4  CAPLUS  COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER:         2002:888555  CAPLUS
DOCUMENT NUMBER:          137:370079
TITLE:                    Preparation of carboxylic acid substituted oxazole
                          derivatives as PPAR-α and -γ activators
                          for treatment of type II diabetes
INVENTOR(S):              Binggeli, Alfred; Boehringer, Markus; Grether, Uwe;
                          Hilpert, Hans; Maerki, Hans-Peter; Meyer, Markus;
                          Mohr, Peter; Ricklin, Fabienne
PATENT ASSIGNEE(S):       F. Hoffmann-La Roche A.-G., Switz.
SOURCE:                   PCT Int. Appl., 179 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.        KIND  DATE          APPLICATION NO.   DATE
     ---------------   ----  --------      ---------------   --------
     WO 2002092084      A1   20021121      WO 2002-EP4962    20020506
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
             PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
             UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
             CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     EP 1392295         A1   20040303      EP 2002-742955    20020506
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
     US 2003055265      A1   20030320      US 2002-142567    20020509
     US 6642389         B2   20031104
     NO 2003005086      A    20031114      NO 2003-5086      20031114
PRIORITY APPLN. INFO.:                  EP 2001-111745    A  20010515
                                        WO 2002-EP4962    W  20020506
OTHER SOURCE(S):          MARPAT 137:370079
GI
```



I

AB The present invention relates to carboxylic acid substituted oxazole derivs. (shown as I; e.g. (S)-2-methoxy-3-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzo[b]thiophen-7-yl]propionic acid) wherein R1 to R7 are as defined below, and pharmaceutically acceptable salts and esters thereof. The compds. are useful for the treatment of diseases such as diabetes, non-insulin dependent diabetes mellitus, elevated blood pressure, increased lipid and cholesterol levels, atherosclerotic diseases or metabolic syndrome. In I: R1 = aryl or heteroaryl; R2, R3, R4 and R6 = H, hydroxy, lower-alkenyl, halogen, lower-alkyl or lower-alkoxy, wherein at least one of R2, R3, R4 and R6 is not H, or R3 and R4 are bonded to each other to form a ring together with the C atoms to which they are attached, and R3 and R4 together are -CH:CH-S-, -S-CH:CH-, -CH:CH-O-, -O-CH:CH-, -CH:CH-CH:CH-, -(CH2)3-5-, -O-(CH2)2-3- or -(CH2)2-3-O-; R5 is lower-alkoxy, lower-alkenyloxy, 2-benzoylanilino, NHCR8:CR9C(O)R10; R7, R8, R9 = H or lower-alkyl; R10 is aryl; n = 1-3; wherein the bond between the C atom Ca and the C atom Cb is a single or double bond. About 160 example prepns. are included. I exhibit IC50 values of 0.1 nM to 50 μM, preferably 1 nM to 10 μM, particularly 1-3500 nM, more preferred 1-500 nM, for PPARα and PPARγ. The compds. further exhibit EC50 values of 0.1 nM to 50 μM, preferably 1 nM to 10 μM, more preferably 1-3500 nM, particularly 1-500 nM, for PPARα and PPARγ.

IT **475480-47-8P**, 2-Ethoxy-3-[2-methyl-4-[(5-methyl-2-phenyloxazol-4-yl)methoxy]phenyl]propionic acid **475480-48-9P**, 2-Ethoxy-3-[2-methyl-4-[(5-methyl-2-(thiophen-2-yl)oxazol-4-yl)methoxy]phenyl]propionic acid **475480-49-0P**, 2-Ethoxy-3-[4-[(2-(4-ethylphenyl)-5-methyloxazol-4-yl)methoxy]-2-methylphenyl]propionic acid **475480-50-3P**, 3-[4-[(2-(4-tert-Butylphenyl)-5-methyloxazol-4-yl)methoxy]-2-methylphenyl]-2-ethoxypropionic acid **475480-51-4P**, 2-Ethoxy-3-[4-[(2-(4-isopropoxyphenyl)-5-methyloxazol-4-yl)methoxy]-2-methylphenyl]propionic acid **475480-55-8P**, 3-[4-[(2-(4-Chlorophenyl)-5-methyloxazol-4-yl)methoxy]-2-methylphenyl]-2-ethoxypropionic acid **475480-58-1P**, 2-Ethoxy-3-[3-methyl-4-[(2-phenyloxazol-4-yl)methoxy]phenyl]propionic acid **475480-62-7P**, 3-[4-[(2-(2-Chlorophenyl)-5-methyloxazol-4-yl)methoxy]-2-methylphenyl]-2-ethoxypropionic acid **475480-63-8P**, 3-[4-[(2-(3-Chlorophenyl)-5-methyloxazol-4-yl)methoxy]-2-methylphenyl]-2-ethoxypropionic acid **475480-65-0P**, 2-Ethoxy-3-[4-[(2-(4-fluoro-3-methylphenyl)-5-methyloxazol-4-yl)methoxy]-2-methylphenyl]propionic acid **475480-66-1P**, 2-Ethoxy-3-[4-[(2-(2-methoxyphenyl)-5-methyloxazol-4-yl)methoxy]-2-methylphenyl]propionic acid

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of carboxylic acid substituted oxazole derivs. as PPAR-α and -γ activators for treatment of type II diabetes)

RN 475480-47-8 CAPLUS

CN Benzenepropanoic acid, α-ethoxy-2-methyl-4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]- (9CI) (CA INDEX NAME)



RN 475480-48-9 CAPLUS

CN Benzenepropanoic acid, α-ethoxy-2-methyl-4-[[5-methyl-2-(2-thienyl)-4-oxazolyl]methoxy]- (9CI) (CA INDEX NAME)



RN 475480-49-0 CAPLUS

CN Benzenepropanoic acid, α-ethoxy-4-[[2-(4-ethylphenyl)-5-methyl-4-oxazolyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 475480-50-3 CAPLUS

CN Benzenepropanoic acid, 4-[[2-[4-(1,1-dimethylethyl)phenyl]-5-methyl-4-oxazolyl]methoxy]-α-ethoxy-2-methyl- (9CI) (CA INDEX NAME)



RN 475480-51-4 CAPLUS

CN Benzenepropanoic acid, α-ethoxy-2-methyl-4-[[5-methyl-2-[4-(1-methylethoxy)phenyl]-4-oxazolyl]methoxy]- (9CI) (CA INDEX NAME)



RN 475480-55-8 CAPLUS

CN Benzenepropanoic acid, 4-[[2-(4-chlorophenyl)-5-methyl-4-oxazolyl]methoxy]-α-ethoxy-2-methyl- (9CI) (CA INDEX NAME)



RN 475480-58-1 CAPLUS

CN Benzenepropanoic acid, α-ethoxy-3-methyl-4-[(2-phenyl-4-oxazolyl)methoxy]- (9CI) (CA INDEX NAME)



RN 475480-62-7 CAPLUS

CN Benzenepropanoic acid, 4-[[2-(2-chlorophenyl)-5-methyl-4-oxazolyl]methoxy]-α-ethoxy-2-methyl- (9CI) (CA INDEX NAME)



RN 475480-63-8 CAPLUS
CN Benzenepropanoic acid, 4-[[2-(3-chlorophenyl)-5-methyl-4-oxazolyl]methoxy]-α-ethoxy-2-methyl- (9CI) (CA INDEX NAME)



RN 475480-65-0 CAPLUS
CN Benzenepropanoic acid, α-ethoxy-4-[[2-(4-fluoro-3-methylphenyl)-5-methyl-4-oxazolyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 475480-66-1 CAPLUS
CN Benzenepropanoic acid, α-ethoxy-4-[[2-(2-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:	2000:117035 CAPLUS
DOCUMENT NUMBER:	132:151814
TITLE:	Preparation of substituted oxazoles and thiazoles as hPPAR gamma and hPPAR alpha activators
INVENTOR(S):	Collins, Jon Loren; Dezube, Milana; Oplinger, Jeffrey Alan; Willson, Timothy Mark
PATENT ASSIGNEE(S):	Glaxo Group Limited, UK
SOURCE:	PCT Int. Appl., 110 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English

```
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

     PATENT NO.          KIND  DATE          APPLICATION NO.   DATE
     ---------------     ----  --------      ---------------   --------
     WO 2000008002        A1   20000217      WO 1999-EP5666    19990805
         W:  AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
             CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN,
             IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG,
             MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,
             TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG,
             KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
             ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
             CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     CA 2339773           AA   20000217      CA 1999-2339773   19990805
     AU 9957310           A1   20000228      AU 1999-57310     19990805
     EP 1102757           A1   20010530      EP 1999-944335    19990805
     EP 1102757           B1   20040414
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO
     TR 200100372         T2   20010921      TR 2001-20010037219990805
     BR 9912866           A    20011030      BR 1999-12866     19990805
     EE 200100074         A    20020617      EE 2001-74        19990805
     AT 264313            E    20040415      AT 1999-944335    19990805
     ZA 2001000983        A    20020305      ZA 2001-983       20010205
     NO 2001000628        A    20010406      NO 2001-628       20010206
     HR 2001000095        A1   20020228      HR 2001-95        20010207
     US 6498174           B1   20021224      US 2001-762445    20010222
PRIORITY APPLN. INFO.:                    GB 1998-17118     A  19980807
                                          WO 1999-EP5666    W  19990805
OTHER SOURCE(S):            MARPAT 132:151814
GI
```



I

AB The title compds. [I; R1 = H, alkyl; R2 = H, alkyl, haloalkyl; R3 = alkyl, cycloalkyl, cycloalkenyl, etc.; R4 = (un)substituted 5-6 membered heterocyclyl containing at least one O, N or S atom, Ph; R5 = H, halo, alkyl, haloalkyl; R6 = H, alkyl; X = O, S; n = 1-3], which are dual activators of hPPARγ and hPPARα, were prepared Thus, refluxing a suspension of (2S)-2-amino-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl}propanoic acid (preparation given) and benzoylacetone in MeOH and trimethylorthoformate afforded 43% (2S)-(Z)-I [R1 = H; R2 = Me; R3 = Ph; R4 = Ph; R5 = H; R6 = Me; X = O; n = 2] which showed 39% glucose reduction in rats.

IT **258346-14-4P 258346-31-5P 258346-32-6P**

258346-33-7P 258346-34-8P 258346-35-9P
258346-36-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted oxazoles and thiazoles as hPPAR gamma and hPPAR alpha activators)

RN 258346-14-4 CAPLUS
CN L-Tyrosine, N-[(1Z)-1-methyl-3-oxo-3-phenyl-1-propenyl]-O-[(5-methyl-2-phenyl-4-oxazolyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 258346-31-5 CAPLUS
CN L-Tyrosine, O-[(5-ethyl-2-phenyl-4-oxazolyl)methyl]-N-[(1Z)-3-oxo-3-phenyl-1-(trifluoromethyl)-1-propenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 258346-32-6 CAPLUS
CN L-Tyrosine, O-[[5-ethyl-2-(4-fluorophenyl)-4-oxazolyl]methyl]-N-[(1Z)-3-oxo-3-phenyl-1-(trifluoromethyl)-1-propenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 258346-33-7 CAPLUS
CN L-Tyrosine, N-[(1Z)-1-ethyl-3-oxo-3-[4-(trifluoromethyl)phenyl]-1-propenyl]-O-[(5-ethyl-2-phenyl-4-oxazolyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 258346-34-8 CAPLUS
CN L-Tyrosine, O-[[5-ethyl-2-(4-fluorophenyl)-4-oxazolyl]methyl]-N-[(1Z)-1-ethyl-3-oxo-3-[4-(trifluoromethyl)phenyl]-1-propenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 258346-35-9 CAPLUS
CN L-Tyrosine, O-[(5-ethyl-2-phenyl-4-oxazolyl)methyl]-N-[(1Z)-1-methyl-3-oxo-3-[4-(trifluoromethyl)phenyl]-1-propenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 258346-36-0 CAPLUS
CN L-Tyrosine, O-[[5-ethyl-2-(4-fluorophenyl)-4-oxazolyl]methyl]-N-[(1Z)-1-methyl-3-oxo-3-[4-(trifluoromethyl)phenyl]-1-propenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



IT **258346-92-8P 258347-07-8P 258347-11-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted oxazoles and thiazoles as hPPAR gamma and hPPAR alpha activators)
RN 258346-92-8 CAPLUS
CN L-Tyrosine, O-[(5-methyl-2-phenyl-4-oxazolyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



```
RN   258347-07-8  CAPLUS
CN   L-Tyrosine, O-[(5-ethyl-2-phenyl-4-oxazolyl)methyl]- (9CI)  (CA INDEX
     NAME)

Absolute stereochemistry.
```



```
RN   258347-11-4  CAPLUS
CN   L-Tyrosine, O-[[5-ethyl-2-(4-fluorophenyl)-4-oxazolyl]methyl]- (9CI)  (CA
     INDEX NAME)

Absolute stereochemistry.
```



```
REFERENCE COUNT:          3     THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
                                RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> FIL REGISTRY
COST IN U.S. DOLLARS                              SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    22.53     178.16

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)        SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -2.77      -2.77

FILE 'REGISTRY' ENTERED AT 12:17:53 ON 25 MAY 2004
```

```
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    24 MAY 2004   HIGHEST RN 685504-43-2
DICTIONARY FILE UPDATES:   24 MAY 2004   HIGHEST RN 685504-43-2

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

   Please note that search-term pricing does apply when
   conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\10679604a.str
```





```
chain nodes :
6  7  14  15  16  17  18  19  20  22
ring nodes :
1  2  3  4  5  8  9  10  11  12  13
chain bonds :
2-20  4-6  6-7  7-8  11-14  14-15  15-16  15-22  16-17  16-19  17-18
ring bonds :
1-2  1-5  2-3  3-4  4-5  8-9  8-13  9-10  10-11  11-12  12-13
exact/norm bonds :
2-3  2-20  3-4  7-8
exact bonds :
1-2  1-5  4-5  4-6  6-7  11-14  14-15  15-16  15-22  17-18
normalized bonds :
8-9  8-13  9-10  10-11  11-12  12-13  16-17  16-19
isolated ring systems :
containing 1 : 8 :


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:CLASS  7:CLASS  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:Atom  14:CLASS  15:CLASS  16:CLASS  17:CLASS  18:CLASS
19:CLASS  20:Atom  22:CLASS
```

```
L5       STRUCTURE UPLOADED

=> d l5
L5 HAS NO ANSWERS
L5                STR
```



```
Structure attributes must be viewed using STN Express query preparation.


=> s l5
SAMPLE SEARCH INITIATED 12:18:14 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     15 TO ITERATE

100.0% PROCESSED      15 ITERATIONS                              0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:           68 TO      532
PROJECTED ANSWERS:               0 TO        0

L6             0 SEA SSS SAM L5

=> s l5 sss full
FULL SEARCH INITIATED 12:18:21 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    521 TO ITERATE

100.0% PROCESSED     521 ITERATIONS                              0 ANSWERS
SEARCH TIME: 00.00.01

L7             0 SEA SSS FUL L5

=> d his

     (FILE 'HOME' ENTERED AT 12:12:21 ON 25 MAY 2004)

     FILE 'REGISTRY' ENTERED AT 12:12:45 ON 25 MAY 2004
L1              STRUCTURE UPLOADED
L2             3 S L1
L3            83 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 12:13:19 ON 25 MAY 2004
L4             4 S L3

     FILE 'REGISTRY' ENTERED AT 12:17:53 ON 25 MAY 2004
L5              STRUCTURE UPLOADED
```

```
L6              0 S L5
L7              0 S L5 SSS FULL

=>
Uploading C:\Program Files\Stnexp\Queries\10679604b.str
```





```
chain nodes :
6  7  14  15  16  17  18  19  21
ring nodes :
1  2  3  4  5  8  9  10  11  12  13
chain bonds :
4-6  6-7  7-8  11-14  14-15  15-16  15-21  16-17  16-19  17-18
ring bonds :
1-2  1-5  2-3  3-4  4-5  8-9  8-13  9-10  10-11  11-12  12-13
exact/norm bonds :
2-3  3-4  7-8
exact bonds :
1-2  1-5  4-5  4-6  6-7  11-14  14-15  15-16  15-21  17-18
normalized bonds :
8-9  8-13  9-10  10-11  11-12  12-13  16-17  16-19
isolated ring systems :
containing 1 : 8 :


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:CLASS  7:CLASS  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:Atom  14:CLASS  15:CLASS  16:CLASS  17:CLASS  18:CLASS
19:CLASS  21:CLASS



L8       STRUCTURE UPLOADED

=> d l8
L8 HAS NO ANSWERS
L8                STR
```



```
Structure attributes must be viewed using STN Express query preparation.


=> s l8
SAMPLE SEARCH INITIATED 12:20:22 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     15 TO ITERATE

100.0% PROCESSED      15 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:           68 TO      532
PROJECTED ANSWERS:               0 TO        0

L9             0 SEA SSS SAM L8

=> s l8 sss full
FULL SEARCH INITIATED 12:20:32 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    521 TO ITERATE

100.0% PROCESSED     521 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

L10            0 SEA SSS FUL L8

=>
Uploading C:\Program Files\Stnexp\Queries\10679604d.str
```





```
chain nodes :
6  7  14  15  16  18
ring nodes :
1  2  3  4  5  8  9  10  11  12  13
chain bonds :
4-6  6-7  7-8  11-14  14-15  15-16  15-18
ring bonds :
1-2  1-5  2-3  3-4  4-5  8-9  8-13  9-10  10-11  11-12  12-13
exact/norm bonds :
2-3  3-4  7-8
exact bonds :
1-2  1-5  4-5  4-6  6-7  11-14  14-15  15-16  15-18
normalized bonds :
8-9  8-13  9-10  10-11  11-12  12-13
isolated ring systems :
containing 1 : 8 :


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:CLASS  7:CLASS  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:Atom  14:CLASS  15:CLASS  16:CLASS  18:CLASS
```

```
L11     STRUCTURE UPLOADED

=> d l11
L11 HAS NO ANSWERS
L11                STR
```



```
Structure attributes must be viewed using STN Express query preparation.


=> s l11
SAMPLE SEARCH INITIATED 12:22:14 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     11 TO ITERATE

100.0% PROCESSED      11 ITERATIONS                             0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:           22 TO       418
PROJECTED ANSWERS:               0 TO         0

L12            0 SEA SSS SAM L11

=> s l11 sss full
FULL SEARCH INITIATED 12:22:20 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    160 TO ITERATE

100.0% PROCESSED     160 ITERATIONS                             0 ANSWERS
SEARCH TIME: 00.00.01

L13            0 SEA SSS FUL L11

=>
Uploading C:\Program Files\Stnexp\Queries\10679604e.str
```





```
chain nodes :
```

```
6  7
ring nodes :
1  2  3  4  5  8  9  10  11  12  13
chain bonds :
4-6  6-7  7-8
ring bonds :
1-2  1-5  2-3  3-4  4-5  8-9  8-13  9-10  10-11  11-12  12-13
exact/norm bonds :
2-3  3-4  7-8
exact bonds :
1-2  1-5  4-5  4-6  6-7
normalized bonds :
8-9  8-13  9-10  10-11  11-12  12-13
isolated ring systems :
containing 1 : 8 :


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:CLASS  7:CLASS  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:Atom



L14     STRUCTURE UPLOADED

=> d l14
L14 HAS NO ANSWERS
L14             STR
```



```
Structure attributes must be viewed using STN Express query preparation.


=> s l14
SAMPLE SEARCH INITIATED 12:23:33 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    110 TO ITERATE

100.0% PROCESSED     110 ITERATIONS                              50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        1571 TO     2829
PROJECTED ANSWERS:           1367 TO     2553

L15          50 SEA SSS SAM L14
```

```
=> s l14 sss full
FULL SEARCH INITIATED 12:23:41 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    2760 TO ITERATE

100.0% PROCESSED    2760 ITERATIONS                              2229 ANSWERS
SEARCH TIME: 00.00.01

L16         2229 SEA SSS FUL L14

=> FIL CAPLUS
COST IN U.S. DOLLARS                                   SINCE FILE      TOTAL
                                                            ENTRY    SESSION
FULL ESTIMATED COST                                        624.20     802.36

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)             SINCE FILE      TOTAL
                                                            ENTRY    SESSION
CA SUBSCRIBER PRICE                                          0.00      -2.77

FILE 'CAPLUS' ENTERED AT 12:23:45 ON 25 MAY 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 25 May 2004  VOL 140 ISS 22
FILE LAST UPDATED: 24 May 2004  (20040524/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.


=> s l16
L17          100 L16

=> s l16 and py<=2002
             100 L16
        22502514 PY<=2002
L18           77 L16 AND PY<=2002

=> s l18 and thu
             137 THU
         2156919 THUS
         2157041 THU
                   (THU OR THUS)
L19           35 L18 AND THU

=> s l19 and p/dt
         4354708 P/DT
L20           34 L19 AND P/DT
```

```
=> s l20 us/pc
MISSING OPERATOR L20 US/PC
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s l20 and us/pc
       1279151 US/PC
L21          21 L20 AND US/PC

=> d l21 ~~ibib abs~~ hitstr 1-10

L21  ANSWER 1 OF 21  CAPLUS  COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER:         2002:521714  CAPLUS
DOCUMENT NUMBER:          137:109278
TITLE:                    Preparation of alkanoic acid derivatives as
                          preventives and/or remedies for diabetes,
                          hyperlipidemia, impaired glucose tolerance, and
                          retinoid-related receptor regulators
INVENTOR(S):              Momose, Yu; Maekawa, Tsuyoshi; Takakura, Nobuyuki;
                          Odaka, Hiroyuki; Kimura, Hiroyuki; Ito, Tatsuya
PATENT ASSIGNEE(S):       Takeda Chemical Industries, Ltd., Japan
SOURCE:                   PCT Int. Appl., 235 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 Japanese
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.       KIND  DATE           APPLICATION NO.  DATE
     ---------------  ----  --------       ---------------  --------
     WO 2002053547     A1    20020711       WO 2001-JP11611  20011228 <--
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS,
             LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL,
             PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,
             UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
             CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     JP 2002265457     A2    20020918       JP 2001-402099   20011228 <--
     EP 1357115        A1    20031029       EP 2001-272544   20011228
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
     US 2004058965     A1    20040325       US 2003-465938   20030626 <--
PRIORITY APPLN. INFO.:                   JP 2000-402648   A  20001228
                                         WO 2001-JP11611  W  20011228
OTHER SOURCE(S):         MARPAT 137:109278
GI
```



I

```
AB   Alkanoic acid derivs. represented by the general formula (I) or salts
     thereof [wherein R1 = optionally substituted five-membered aromatic
     heterocyclic group; X = a bond, O, S, CO, C(:S), CR4(OR6), NR6 (wherein R4
```

= H, optionally substituted hydrocarbyl; R5 = H, hydroxy-protecting group;
R6 = H, optionally hydrocarbyl, amino-protecting group); Q = C1-20
divalent hydrocarbon group; Y = bond, O, S, S(:O), SO2, NR7, CONR7, NR7CO,
(wherein R7 = H, optionally substituted hydrocarbon group,
amino-protecting group); ; ring A = an aromatic ring which may have one to
three substituents; Z = (CH2)n-Z1 (wherein n = an integer of 1 to 8; Z1 =
O, S, SO, SO2, NR16; wherein R16 = H, optionally substituted hydrocarbon
group); ring B = an optionally mono- to tri-substituted pyridine, benzene,
or naphthalene ring; U = a bond, O, S, SOP, SO2; W = C1-20 divalent
hydrocarbon group; R3; R3 = OH, optionally substituted hydrocarbyloxy,
NR9R10 (wherein R9, R10 = H, optionally substituted hydrocarbyl,
heterocyclyl, or acyl; or R9 and R10 are linked to each other to form a
ring); with the proviso that when B is an optionally mono- to
tri-substituted benzene ring, U is a bond] are prepared Also disclosed are
preventives and/or remedies for diabetes, hyperlipidemia, and impaired
glucose tolerance, retinoid-related receptor regulators, ligands for
peroxisome-proliferator response receptor and retinoid X receptor, insulin
resistance improvers containing the compds. I or salts or prodrugs thereof.
Thus, a 40% toluene solution (1.74 g) of di-Et azodicarboxylate was
added dropwise to a mixture of 3-(5-methyl-2-phenyl-4-oxazolylmethoxy)-5-
isoxazolylmethanol 0.859, Me 2-(2-hydroxyphenyl)acetate 0.499, Ph3P 0.944,
and 15 mL THF at room temperature and stirred for 15 h to give Me
2-[2-[3-(5-methyl-2-phenyl-4-oxazolylmethoxy)-5-
isoxazolylmethoxy]phenyl]acetate as an oil which was dissolved in MeOH/THF
(1/1, 20 mL), treated with 10 mL 1 N aqueous NaOH, stirred at room temperature
for
15 h, and acidified with 1 N aqueous HCl to give 52% 2-[2-[3-(5-methyl-2-
phenyl-4-oxazolylmethoxy)-5-isoxazolylmethoxy]phenyl]acetic acid (II).
When a feed containing 0.005% II was fed freely to type II diabetic mice for 4
days, the blood sugar and lipid level was lowered by 54 and 96%, resp. A
capsule and a tablet formulation containing 2-[2-ethoxy-5-[4-[(5-methyl-2-
phenyl-4-oxazolyl)methoxy]benzyloxy]phenyl]acetic acid Me ester were
prepared

IT **441354-85-4P**, 2-[3-[4-[(5-Methyl-2-phenyl-4-
oxazolyl)methoxy]benzyloxy]phenyl]acetic acid **441354-87-6P**,
2-[3-[4-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]phenyl]propionic
acid ethyl ester **441354-88-7P**, 2-[3-[4-[(5-Methyl-2-phenyl-4-
oxazolyl)methoxy]benzyloxy]phenyl]propionic acid **441354-89-8P**,
2-[2-Ethoxy-5-[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]phenyl]a
cetic acid methyl ester **441354-90-1P**, 2-[2-Ethoxy-5-[4-[(5-
methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]phenyl]acetic acid
441354-91-2P, 3-[2-Ethoxy-5-[4-[(5-methyl-2-phenyl-4-
oxazolyl)methoxy]benzyloxy]phenyl]propionic acid ethyl ester
441354-92-3P, 3-[2-Ethoxy-5-[4-[(5-methyl-2-phenyl-4-
oxazolyl)methoxy]benzyloxy]phenyl]propionic acid **441354-93-4P**,
2-[4-[4-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]phenyl]acetic
acid methyl ester **441354-94-5P**, 2-[4-[4-[(5-Methyl-2-phenyl-4-
oxazolyl)methoxy]benzyloxy]phenyl]acetic acid **441354-95-6P**,
2-[2-[4-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]phenyl]acetic
acid ethyl ester **441354-96-7P**, 2-[2-[4-[(5-Methyl-2-phenyl-4-
oxazolyl)methoxy]benzyloxy]phenyl]acetic acid **441354-97-8P**,
3-[2-[4-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]phenyl]propionic
acid methyl ester **441354-98-9P**, 3-[2-[4-[(5-Methyl-2-phenyl-4-
oxazolyl)methoxy]benzyloxy]phenyl]propionic acid **441354-99-0P**,
2-[5-Methyl-2-[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]phenyl]a
cetic acid methyl ester **441355-00-6P**, 2-[5-Methyl-2-[4-[(5-
methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]phenyl]acetic acid
441355-01-7P, 2-[5-Hydroxy-2-[4-[(5-methyl-2-phenyl-4-
oxazolyl)methoxy]benzyloxy]phenyl]acetic acid **441355-02-8P**,
2-[5-Chloro-2-[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]phenyl]a

cetic acid methyl ester **441355-03-9P**, 2-[5-Chloro-2-[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]phenyl]acetic acid **441355-04-0P**, 2-[5-Bromo-2-[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]phenyl]acetic acid methyl ester **441355-05-1P**, 2-[5-Bromo-2-[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]phenyl]acetic acid **441355-06-2P**, 2-[2-[4-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]-5-phenylphenyl]acetic acid methyl ester **441355-07-3P**, 2-[2-[4-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]-5-phenylphenyl]acetic acid **441355-08-4P**, 2-[5-Methoxy-2-[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]phenyl] acetic acid methyl ester **441355-09-5P**, 2-[5-Methoxy-2-[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]phenyl]acetic acid **441355-10-8P**, 2-[5-Ethoxy-2-[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]phenyl]acetic acid methyl ester **441355-11-9P**, 2-[5-Ethoxy-2-[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]phenyl]acetic acid **441355-12-0P**, 2-[5-Benzyloxy-2-[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]phenyl]acetic acid **441355-13-1P**, 3-[5-Ethoxy-2-[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]phenyl]propionic acid ethyl ester **441355-14-2P**, 3-[5-Ethoxy-2-[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]phenyl]propionic acid **441355-15-3P**, 2-[2-[3-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]phenyl]acetic acid methyl ester **441355-16-4P**, 2-[2-[3-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]phenyl]acetic acid **441355-17-5P**, 2-[[3-[3-(5-Methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]phenyl]acetic acid **441355-18-6P**, 3-[2-Ethoxy-5-[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]phenyl]propionic acid **441355-19-7P**, 2-[3-[2-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]phenyl]acetic acid **441355-20-0P**, 3-[2-Ethoxy-5-[2-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]phenyl]propionic acid **441355-21-1P**, 2-[2-[4-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]-3-pyridyl]acetic acid **441355-22-2P**, 2-[3-[4-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]-2-pyridyl]acetic acid **441355-23-3P**, 2-[5-[4-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]-2-pyridyl]acetic acid **441355-24-4P**, 2-[2-[4-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]-1-naphthyl]acetic acid **441355-29-9P**, 3-[4-[4-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]phenyl]propionic acid ethyl ester **441355-30-2P**, 3-[4-[4-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]phenyl]propionic acid **441355-31-3P**, 3-[2-[4-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]-1-naphthyl]propionic acid **441355-32-4P**, 2-[2-[3-Methoxy-4-[(2-phenyl-5-methyl-4-oxazolyl)methoxy]benzyloxy]phenyl]acetic acid **441355-33-5P**, 2-[2-[4-Methoxy-3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]phenyl]acetic acid **441355-34-6P**, 2-[2-[4-[[2-(2-Furyl)-5-methyl-4-oxazolyl]methoxy]benzyloxy]phenyl]acetic acid **441355-37-9P**, 2-[3-[4-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]phenyl]acetic acid 4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]benzyl ester **441355-38-0P**, 3-(2-(4-((5-Methyl-2-phenyl-4-oxazolyl)methoxy)benzyloxy)-1-naphthyl)propenoic acid ethyl ester **441355-39-1P**, 2-[2-[2-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]phenyl]acetic acid methyl ester **441355-40-4P**, 2-[2-[2-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]phenyl]acetic acid **441355-49-3P**, 3-[2-Ethoxy-4-[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]phenyl]propionic acid methyl ester **441355-50-6P**, 3-[2-Ethoxy-4-[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]phenyl]propionic acid **441355-51-7P**, 3-[4-[[4-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]benzyl]sulfanyl]phenyl]propionic acid **441355-52-8P**, 2-[4-[3-[(5-Methyl-2-phenyl-4-

oxazolyl)methoxy]benzyloxy]phenyl]acetic acid **441355-53-9P**, 2-[4-[2-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]phenyl]acetic acid **441355-54-0P**, 3-[2-Ethoxy-4-[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]phenyl]propionic acid ethyl ester **441355-55-1P**, 3-[2-Ethoxy-4-[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]phenyl]propionic acid **441355-56-2P**, 3-[2-Ethoxy-4-[2-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]phenyl]propionic acid ethyl ester **441355-57-3P**, 3-[2-Ethoxy-4-[2-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]phenyl]propionic acid **441355-60-8P**, 2-[5-[3-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]-3-pyridyl]acetic acid **441355-66-4P**, 2-[2-[4-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]-5-propylphenyl]acetic acid methyl ester **441355-67-5P**, 2-[2-[4-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]-5-propylphenyl]acetic acid **441355-68-6P**, 2-[2-[4-[(2-Phenyl-5-propyl-4-oxazolyl)methoxy]benzyloxy]phenyl]acetic acid methyl ester **441355-69-7P**, 2-[2-[4-[(2-Phenyl-5-propyl-4-oxazolyl)methoxy]benzyloxy]phenyl]acetic acid **441355-70-0P**, 2-[3-[4-[(2-Phenyl-5-propyl-4-oxazolyl)methoxy]benzyloxy]phenyl]acetic acid methyl ester **441355-71-1P**, 2-[3-[4-[(2-Phenyl-5-propyl-4-oxazolyl)methoxy]benzyloxy]phenyl]acetic acid **441355-75-5P**, 2-[2-[3-Methoxy-4-[(2-phenyl-5-methyl-4-oxazolyl)methoxy]benzyloxy]-3-pyridyl]acetic acid **441355-76-6P**, 2-[2-[4-[[2-(2-Furyl)-5-methyl-4-oxazolyl)methoxy]benzyloxy]-3-pyridyl]acetic acid **441355-82-4P**, 2-[2-[[2-[2-(5-Methyl-2-phenyl-4-oxazolyl)ethyl]-4-oxazolyl]methoxy]phenyl]acetic acid methyl ester **441355-83-5P**, 2-[2-[[2-[2-(5-Methyl-2-phenyl-4-oxazolyl)ethyl]-4-oxazolyl]methoxy]phenyl]acetic acid **441355-84-6P**, 2-[3-[[2-[2-(5-Methyl-2-phenyl-4-oxazolyl)ethyl]-4-oxazolyl]methoxy]phenyl]acetic acid methyl ester **441355-85-7P**, 2-[3-[[2-[2-(5-Methyl-2-phenyl-4-oxazolyl)ethyl]-4-oxazolyl]methoxy]phenyl]acetic acid **441355-94-8P**, 2-[6-Methyl-2-[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]-3-pyridyl]acetic acid **441356-09-8P**, 2-[2-[[4-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]phenoxy]methyl]-3-pyridyl]acetic acid **441356-14-5P**, 2-[2-[4-[5-Methyl-2-(2-naphthyl)-4-oxazolylmethoxy]benzloxy]-3-pyridyl]acetic acid **441356-15-6P**, 3-[4-Methoxy-3-[(2-phenyl-5-methyl-4-oxazolyl)methoxy]benzyloxy]phenyl]acetic acid methyl ester **441356-16-7P**, 3-[4-Methoxy-3-[(2-phenyl-5-methyl-4-oxazolyl)methoxy]benzyloxy]phenyl]acetic acid **441356-17-8P**, 3-[2-[4-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]-3-pyridyl]propenoic acid ethyl ester **441356-18-9P**, 3-[2-[4-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]-3-pyridyl]propenoic acid **441356-19-0P**, 3-[2-[4-[[2-(2-Furyl)-5-methyl-4-oxazolyl]methoxy]-3-methoxy-benzyloxy]-3-pyridyl]propenoic acid ethyl ester **441356-20-3P**, 2-[2-[4-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]-3-pyridyl]acetic acid lithium salt **441356-21-4P**, 2-[2-[4-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]-3-pyridyl]acetic acid calcium salt **441356-22-5P**, 2-[2-[4-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]-3-pyridyl]acetic acid potassium salt **441356-23-6P**, 2-[3-[3-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]benzylthio]phenyl]acetic acid **441356-24-7P**, 3-[3-[3-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]benzylthio]phenyl]propionic acid **441356-25-8P**, 2-[3-Chloro-4-[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]benzylthio]phenyl]acetic acid methyl ester **441356-26-9P**, 2-[3-Chloro-4-[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]benzylthio]phenyl]acetic acid **441356-27-0P**, 3-[4-[3-[4-Methoxy-3-(5-methyl-2-phenyl-4-oxazolyl)methoxy]benzylthio]phenyl]propionic acid **441356-28-1P**, 3-[4-[3-[3-(5-Methyl-2-phenyl-4-

oxazolyl)methoxy]benzylthio]phenyl]propionic acid **441356-29-2P**, 2-[2-([4-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]benzyl]oxy)pyridin-3-yl]ethanol **441356-30-5P**, 2-[2-[4-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]-3-pyridyl]acetic acid sodium salt **441357-66-0P**, 3-[2-[4-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]-1-naphthyl]propionic acid ethyl ester
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of alkanoic acid derivs. as retinoid-related receptor regulators and preventive and/or therapeutic agents for diabetes, hyperlipidemia and impaired glucose tolerance)

RN 441354-85-4 CAPLUS
CN Benzeneacetic acid, 3-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441354-87-6 CAPLUS
CN Benzeneacetic acid, α-methyl-3-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 441354-88-7 CAPLUS
CN Benzeneacetic acid, α-methyl-3-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441354-89-8 CAPLUS
CN Benzeneacetic acid, 2-ethoxy-5-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 441354-90-1 CAPLUS
CN Benzeneacetic acid, 2-ethoxy-5-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441354-91-2 CAPLUS
CN Benzenepropanoic acid, 2-ethoxy-5-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 441354-92-3 CAPLUS
CN Benzenepropanoic acid, 2-ethoxy-5-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441354-93-4 CAPLUS
CN Benzeneacetic acid, 4-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 441354-94-5 CAPLUS
CN Benzeneacetic acid, 4-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441354-95-6 CAPLUS
CN Benzeneacetic acid, 2-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 441354-96-7 CAPLUS
CN Benzeneacetic acid, 2-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441354-97-8 CAPLUS
CN Benzenepropanoic acid, 2-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 441354-98-9 CAPLUS
CN Benzenepropanoic acid, 2-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441354-99-0 CAPLUS
CN Benzeneacetic acid, 5-methyl-2-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 441355-00-6 CAPLUS
CN Benzeneacetic acid, 5-methyl-2-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441355-01-7 CAPLUS
CN Benzeneacetic acid, 5-hydroxy-2-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441355-02-8 CAPLUS
CN Benzeneacetic acid, 5-chloro-2-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 441355-03-9 CAPLUS
CN Benzeneacetic acid, 5-chloro-2-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441355-04-0 CAPLUS
CN Benzeneacetic acid, 5-bromo-2-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 441355-05-1 CAPLUS
CN Benzeneacetic acid, 5-bromo-2-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441355-06-2 CAPLUS
CN [1,1'-Biphenyl]-3-acetic acid, 4-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 441355-07-3 CAPLUS
CN [1,1'-Biphenyl]-3-acetic acid, 4-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441355-08-4 CAPLUS
CN Benzeneacetic acid, 5-methoxy-2-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 441355-09-5 CAPLUS
CN Benzeneacetic acid, 5-methoxy-2-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441355-10-8 CAPLUS
CN Benzeneacetic acid, 5-ethoxy-2-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 441355-11-9 CAPLUS
CN Benzeneacetic acid, 5-ethoxy-2-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441355-12-0 CAPLUS
CN Benzeneacetic acid, 2-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-5-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 441355-13-1 CAPLUS
CN Benzenepropanoic acid, 5-ethoxy-2-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 441355-14-2 CAPLUS
CN Benzenepropanoic acid, 5-ethoxy-2-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441355-15-3 CAPLUS
CN Benzeneacetic acid, 2-[[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 441355-16-4 CAPLUS
CN Benzeneacetic acid, 2-[[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441355-17-5 CAPLUS
CN Benzeneacetic acid, 3-[[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441355-18-6 CAPLUS
CN Benzenepropanoic acid, 2-ethoxy-5-[[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441355-19-7 CAPLUS
CN Benzeneacetic acid, 3-[[2-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441355-20-0 CAPLUS
CN Benzenepropanoic acid, 2-ethoxy-5-[[2-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441355-21-1 CAPLUS
CN 3-Pyridineacetic acid, 2-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441355-22-2 CAPLUS
CN 2-Pyridineacetic acid, 3-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441355-23-3 CAPLUS
CN 2-Pyridineacetic acid, 5-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441355-24-4 CAPLUS
CN 1-Naphthaleneacetic acid, 2-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441355-29-9 CAPLUS
CN Benzenepropanoic acid, 4-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 441355-30-2 CAPLUS
CN Benzenepropanoic acid, 4-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441355-31-3 CAPLUS
CN 1-Naphthalenepropanoic acid, 2-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441355-32-4 CAPLUS
CN Benzeneacetic acid, 2-[[3-methoxy-4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441355-33-5 CAPLUS
CN Benzeneacetic acid, 2-[[4-methoxy-3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441355-34-6 CAPLUS
CN Benzeneacetic acid, 2-[[4-[[2-(2-furanyl)-5-methyl-4-oxazolyl]methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441355-37-9 CAPLUS
CN Benzeneacetic acid, 3-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-, [4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 441355-38-0 CAPLUS
CN 2-Propenoic acid, 3-[2-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-1-naphthalenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 441355-39-1 CAPLUS
CN Benzeneacetic acid, 2-[[2-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 441355-40-4 CAPLUS
CN Benzeneacetic acid, 2-[[2-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441355-49-3 CAPLUS
CN Benzenepropanoic acid, 2-ethoxy-4-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 441355-50-6 CAPLUS
CN Benzenepropanoic acid, 2-ethoxy-4-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441355-51-7 CAPLUS
CN Benzenepropanoic acid, 4-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]thio]- (9CI) (CA INDEX NAME)



RN 441355-52-8 CAPLUS
CN Benzeneacetic acid, 4-[[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441355-53-9 CAPLUS
CN Benzeneacetic acid, 4-[[2-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441355-54-0 CAPLUS
CN Benzenepropanoic acid, 2-ethoxy-4-[[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 441355-55-1 CAPLUS
CN Benzenepropanoic acid, 2-ethoxy-4-[[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441355-56-2 CAPLUS
CN Benzenepropanoic acid, 2-ethoxy-4-[[2-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 441355-57-3 CAPLUS
CN Benzenepropanoic acid, 2-ethoxy-4-[[2-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441355-60-8 CAPLUS
CN 3-Pyridineacetic acid, 5-[[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441355-66-4 CAPLUS
CN Benzeneacetic acid, 2-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-5-propyl-, methyl ester (9CI) (CA INDEX NAME)



RN 441355-67-5 CAPLUS
CN Benzeneacetic acid, 2-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-5-propyl- (9CI) (CA INDEX NAME)



RN 441355-68-6 CAPLUS
CN Benzeneacetic acid, 2-[[4-[(2-phenyl-5-propyl-4-oxazolyl)methoxy]phenyl]methoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 441355-69-7 CAPLUS
CN Benzeneacetic acid, 2-[[4-[(2-phenyl-5-propyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441355-70-0 CAPLUS
CN Benzeneacetic acid, 3-[[4-[(2-phenyl-5-propyl-4-oxazolyl)methoxy]phenyl]methoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 441355-71-1 CAPLUS

CN Benzeneacetic acid, 3-[[4-[(2-phenyl-5-propyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441355-75-5 CAPLUS

CN 3-Pyridineacetic acid, 2-[[3-methoxy-4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441355-76-6 CAPLUS

CN 3-Pyridineacetic acid, 2-[[4-[[2-(2-furanyl)-5-methyl-4-oxazolyl]methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441355-82-4 CAPLUS

CN Benzeneacetic acid, 2-[[2-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]-4-oxazolyl]methoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 441355-83-5 CAPLUS
CN Benzeneacetic acid, 2-[[2-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]-4-oxazolyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441355-84-6 CAPLUS
CN Benzeneacetic acid, 3-[[2-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]-4-oxazolyl]methoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 441355-85-7 CAPLUS
CN Benzeneacetic acid, 3-[[2-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]-4-oxazolyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441355-94-8 CAPLUS
CN 3-Pyridineacetic acid, 6-methyl-2-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441356-09-8 CAPLUS
CN 3-Pyridineacetic acid, 2-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 441356-14-5 CAPLUS
CN 3-Pyridineacetic acid, 2-[[4-[[5-methyl-2-(2-naphthalenyl)-4-oxazolyl]methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441356-15-6 CAPLUS
CN Benzeneacetic acid, 4-methoxy-3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 441356-16-7 CAPLUS
CN Benzeneacetic acid, 4-methoxy-3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]-

(9CI) (CA INDEX NAME)



RN 441356-17-8 CAPLUS
CN 2-Propenoic acid, 3-[2-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-3-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 441356-18-9 CAPLUS
CN 2-Propenoic acid, 3-[2-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 441356-19-0 CAPLUS
CN 2-Propenoic acid, 3-[2-[[4-[[2-(2-furanyl)-5-methyl-4-oxazolyl]methoxy]-3-methoxyphenyl]methoxy]-3-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 441356-20-3 CAPLUS
CN 3-Pyridineacetic acid, 2-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-, lithium salt (9CI) (CA INDEX NAME)



● Li

RN 441356-21-4 CAPLUS
CN 3-Pyridineacetic acid, 2-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-, calcium salt (9CI) (CA INDEX NAME)



●1/2 Ca

RN 441356-22-5 CAPLUS
CN 3-Pyridineacetic acid, 2-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-, potassium salt (9CI) (CA INDEX NAME)



● K

RN 441356-23-6 CAPLUS
CN Benzeneacetic acid, 3-[[[3-[(5-methyl-2-phenyl-4-

oxazolyl)methoxy]phenyl]methyl]thio]- (9CI) (CA INDEX NAME)



RN 441356-24-7 CAPLUS
CN Benzenepropanoic acid, 3-[[[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]thio]- (9CI) (CA INDEX NAME)



RN 441356-25-8 CAPLUS
CN Benzeneacetic acid, 3-chloro-4-[[[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]thio]-, methyl ester (9CI) (CA INDEX NAME)



RN 441356-26-9 CAPLUS
CN Benzeneacetic acid, 3-chloro-4-[[[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]thio]- (9CI) (CA INDEX NAME)



RN 441356-27-0 CAPLUS
CN Benzenepropanoic acid, 4-[[[4-methoxy-3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]thio]- (9CI) (CA INDEX NAME)



RN 441356-28-1 CAPLUS
CN Benzenepropanoic acid, 4-[[[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]thio]- (9CI) (CA INDEX NAME)



RN 441356-29-2 CAPLUS
CN 3-Pyridineethanol, 2-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441356-30-5 CAPLUS
CN 3-Pyridineacetic acid, 2-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-, sodium salt (9CI) (CA INDEX NAME)



RN 441357-66-0 CAPLUS
CN 1-Naphthalenepropanoic acid, 2-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-, ethyl ester (9CI) (CA INDEX NAME)



IT 159018-03-8, 4-[5-Methyl-2-(2-naphthyl)-4-oxazolylmethoxy]benzaldehyde **174258-31-2**, [3-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methanol **174258-32-3**, 4-(3-Chloromethylphenoxymethyl)-5-methyl-2-phenyloxazole **178610-66-7**, 4-Methoxy-3-(5-methyl-2-phenyl-4-oxazolylmethoxy)benzaldehyde **250602-52-9** **250602-98-3**, 4-(2-Chloromethylphenoxymethyl)-5-methyl-2-phenyloxazole **250603-01-1**, [4-[[2-(2-Furyl)-5-methyl-4-oxazolyl]methoxy]-3-methoxyphenyl]methanol **250603-03-3** **441356-53-2**, 4-[[2-(2-Furyl)-5-methyl-4-oxazolyl]methoxy]benzaldehyde **441357-59-1**, 4-(4-Chloromethyl-3-methoxyphenoxymethyl)-2-phenyl-5-methyloxazole

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of alkanoic acid derivs. as retinoid-related receptor regulators and preventive and/or therapeutic agents for diabetes, hyperlipidemia and impaired glucose tolerance)

RN 159018-03-8 CAPLUS

CN Benzaldehyde, 4-[[5-methyl-2-(2-naphthalenyl)-4-oxazolyl]methoxy]- (9CI) (CA INDEX NAME)



RN 174258-31-2 CAPLUS

CN Benzenemethanol, 3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]- (9CI) (CA INDEX NAME)



RN 174258-32-3 CAPLUS

CN Oxazole, 4-[[3-(chloromethyl)phenoxy]methyl]-5-methyl-2-phenyl- (9CI) (CA INDEX NAME)



RN 178610-66-7 CAPLUS
CN Benzaldehyde, 4-methoxy-3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]- (9CI) (CA INDEX NAME)



RN 250602-52-9 CAPLUS
CN Benzenemethanol, 4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]- (9CI) (CA INDEX NAME)



RN 250602-98-3 CAPLUS
CN Oxazole, 4-[[2-(chloromethyl)phenoxy]methyl]-5-methyl-2-phenyl- (9CI) (CA INDEX NAME)



RN 250603-01-1 CAPLUS
CN Benzenemethanol, 4-[[2-(2-furanyl)-5-methyl-4-oxazolyl]methoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 250603-03-3 CAPLUS

CN Benzenemethanol, 3-methoxy-4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]- (9CI) (CA INDEX NAME)



RN 441356-53-2 CAPLUS

CN Benzaldehyde, 4-[[2-(2-furanyl)-5-methyl-4-oxazolyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441357-59-1 CAPLUS

CN Oxazole, 4-[[4-(chloromethyl)-3-methoxyphenoxy]methyl]-5-methyl-2-phenyl- (9CI) (CA INDEX NAME)



IT **250602-53-0P**, 4-(4-Chloromethylphenoxymethyl)-5-methyl-2-phenyloxazole **342024-28-6P**, [[4-Methoxy-3-(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methanol **342024-29-7P**, 4-(5-Chloromethyl-2-methoxyphenoxymethyl)-5-methyl-2-phenyloxazole **441356-44-1P**, 2-[5-Methoxymethoxy-2-[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]phenyl]acetonitrile **441356-45-2P**, 2-[5-Hydroxy-2-[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]phenyl]acetonitrile **441356-46-3P**, 2-[5-Benzyloxy-2-[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]phenyl]acetonitrile

441356-48-5P, 5-[4-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]-3-pyridinecarboxylic acid methyl ester **441356-49-6P**, [5-[4-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]-3-pyridyl]methanol **441356-50-9P**, 2-[5-[4-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]-3-pyridyl]acetonitrile **441356-51-0P**, 2-[2-[4-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]-1-naphthyl]acetonitrile **441356-52-1P**, 4-[4-(4-Benzoyl-3-hydroxyphenoxymethyl)phenoxymethyl]-5-methyl-2-phenyloxazole **441356-54-3P**, [4-[[2-(2-Furyl)-5-methyl-4-oxazolyl]methoxy]phenyl]methanol **441356-63-4P**, 3-Cyano-2-[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]pyridine **441356-64-5P**, 2-[4-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]-3-pyridinecarbaldehyde **441356-65-6P**, [2-[4-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]-3-pyridyl]methanol **441356-66-7P**, 2-[2-[4-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]-3-pyridyl]acetonitrile **441356-67-8P**, 3-[4-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]pyridine-2-carboxylic acid methyl ester **441356-68-9P**, [3-[4-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]-2-pyridyl]methanol **441356-69-0P**, 2-[3-[4-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]-2-pyridyl]acetonitrile **441356-70-3P**, 2-[5-[4-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]-2-propylphenoxy]acetic acid methyl ester **441356-71-4P**, 2-[5-[4-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]-2-propylphenoxy]acetic acid **441356-72-5P**, 2-[2-Benzoyl-5-[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]phenoxy]acetic acid methyl ester **441356-73-6P**, 2-[2-Benzoyl-5-[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]phenoxy]acetic acid **441356-76-9P**, [5-[3-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]-3-pyridyl]methanol **441356-78-1P**, 2-[5-[3-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]-3-pyridyl]acetonitrile **441356-89-4P**, 4-[(2-Phenyl-5-propyl-4-oxazolyl)methoxy]benzaldehyde **441356-90-7P**, [4-[(2-Phenyl-5-propyl-4-oxazolyl)methoxy]phenyl]methanol **441356-95-2P** **441356-96-3P**, 2-[3-Methoxy-4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]nicotinaldehyde **441356-97-4P**, [2-[3-Methoxy-4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]-3-pyridyl]methanol **441356-98-5P** **441356-99-6P** **441357-00-2P**, 2-[4-[[2-(2-Furyl)-5-methyl-4-oxazolyl]methoxy]benzyloxy]nicotinaldehyde **441357-01-3P**, [2-[4-[[2-(2-Furyl)-5-methyl-4-oxazolyl]methoxy]benzyloxy]-3-pyridyl]methanol **441357-02-4P** **441357-13-7P** **441357-14-8P**, 6-Methyl-2-[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]nicotinaldehyde **441357-16-0P** **441357-27-3P**, 4-[(4-Benzyloxyphenoxy)methyl]-5-methyl-2-phenyloxazole **441357-28-4P**, 4-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy)phenol **441357-31-9P**, 2-[[4-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]phenoxy]methyl]nicotinic acid ethyl ester **441357-32-0P**, 2-[[4-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]phenoxy]methyl]-3-pyridyl]methanol **441357-33-1P**, 2-[2-[[4-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]phenoxy]methyl]-3-pyridyl]acetonitrile **441357-43-3P**, 4-[5-Methyl-2-(2-naphthyl)-4-oxazolylmethoxy]benzyl alcohol **441357-44-4P**, 2-[4-[5-Methyl-2-(2-naphthyl)-4-oxazolylmethoxy]benzyloxy]nicotinonitrile **441357-45-5P**, 2-[4-[5-Methyl-2-(2-naphthyl)-4-oxazolylmethoxy]benzyloxy]pyridine-3-carboxaldehyde **441357-46-6P**, [2-[4-[5-Methyl-2-(2-naphthyl)-4-oxazolylmethoxy]benzyloxy]-3-pyridyl]methanol **441357-47-7P**, 2-[2-[4-[5-Methyl-2-(2-naphthyl)-4-oxazolylmethoxy]benzyloxy]-3-pyridyl]acetonitrile **441357-49-9P**, 3-Cyano-2-[4-[[2-(2-furyl)-5-methyl-4-oxazolyl]methoxy]-3-methoxybenzyloxy]pyridine **441357-50-2P**, 2-[4-[[2-(2-Furyl)-5-

methyl-4-oxazolyl]methoxy]-3-methoxybenzyloxy]-3-pyridinecarbaldehyde **441357-51-3P**, 3-[3-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]benzylthio]benzoic acid **441357-52-4P**, 3-[3-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]benzylthio]benzoic acid methyl ester **441357-53-5P**, 3-[3-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]benzylthio]benzaldehyde **441357-54-6P**, 2-[3-[3-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]benzylthio]benzyl]malonic acid ethyl ester **441357-55-7P**, 2-[3-[3-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]benzylthio]phenyl]acetonitrile **441357-56-8P**, Hydroxy[2-([4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]benzyl]oxy)pyridin-3-yl]methanesulfonic acid sodium **441357-57-9P**, 2-([4-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]benzyl]oxy)-3-oxiran-2-ylpyridine **441357-65-9P**, 5-[3-[(5-Methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]nicotinic acid methyl ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of alkanoic acid derivs. as retinoid-related receptor regulators and preventive and/or therapeutic agents for diabetes, hyperlipidemia and impaired glucose tolerance)

RN 250602-53-0 CAPLUS
CN Oxazole, 4-[[4-(chloromethyl)phenoxy]methyl]-5-methyl-2-phenyl- (9CI) (CA INDEX NAME)



RN 342024-28-6 CAPLUS
CN Benzenemethanol, 4-methoxy-3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]- (9CI) (CA INDEX NAME)



RN 342024-29-7 CAPLUS
CN Oxazole, 4-[[5-(chloromethyl)-2-methoxyphenoxy]methyl]-5-methyl-2-phenyl- (9CI) (CA INDEX NAME)



RN 441356-44-1 CAPLUS

CN Benzeneacetonitrile, 5-(methoxymethoxy)-2-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441356-45-2 CAPLUS

CN Benzeneacetonitrile, 5-hydroxy-2-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441356-46-3 CAPLUS

CN Benzeneacetonitrile, 2-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-5-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 441356-48-5 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 441356-49-6 CAPLUS
CN 3-Pyridinemethanol, 5-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441356-50-9 CAPLUS
CN 3-Pyridinecarbonitrile, 5-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441356-51-0 CAPLUS
CN 1-Naphthaleneacetonitrile, 2-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441356-52-1 CAPLUS
CN Methanone, [2-hydroxy-4-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]phenyl]phenyl- (9CI) (CA INDEX NAME)



RN 441356-54-3 CAPLUS
CN Benzenemethanol, 4-[[2-(2-furanyl)-5-methyl-4-oxazolyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441356-63-4 CAPLUS
CN 3-Pyridinecarbonitrile, 2-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441356-64-5 CAPLUS
CN 3-Pyridinecarboxaldehyde, 2-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441356-65-6 CAPLUS
CN 3-Pyridinemethanol, 2-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441356-66-7 CAPLUS
CN 3-Pyridineacetonitrile, 2-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441356-67-8 CAPLUS
CN 2-Pyridinecarboxylic acid, 3-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 441356-68-9 CAPLUS
CN 2-Pyridinemethanol, 3-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441356-69-0 CAPLUS
CN 2-Pyridineacetonitrile, 3-[[4-[(5-methyl-2-phenyl-4-

oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441356-70-3 CAPLUS
CN Acetic acid, [5-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-2-propylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 441356-71-4 CAPLUS
CN Acetic acid, [5-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-2-propylphenoxy]- (9CI) (CA INDEX NAME)



RN 441356-72-5 CAPLUS
CN Acetic acid, [2-benzoyl-5-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 441356-73-6 CAPLUS
CN Acetic acid, [2-benzoyl-5-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 441356-76-9 CAPLUS
CN 3-Pyridinecarboxylic acid, 5-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441356-78-1 CAPLUS
CN 3-Pyridineacetonitrile, 5-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441356-89-4 CAPLUS
CN Benzaldehyde, 4-[(2-phenyl-5-propyl-4-oxazolyl)methoxy]- (9CI) (CA INDEX NAME)



RN 441356-90-7 CAPLUS
CN Benzenemethanol, 4-[(2-phenyl-5-propyl-4-oxazolyl)methoxy]- (9CI) (CA INDEX NAME)



RN 441356-95-2 CAPLUS

CN 3-Pyridinecarbonitrile, 2-[[3-methoxy-4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441356-96-3 CAPLUS

CN 3-Pyridinecarboxaldehyde, 2-[[3-methoxy-4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441356-97-4 CAPLUS

CN 3-Pyridinemethanol, 2-[[3-methoxy-4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441356-98-5 CAPLUS

CN 3-Pyridineacetonitrile, 2-[[3-methoxy-4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441356-99-6 CAPLUS
CN 3-Pyridinecarbonitrile, 2-[[4-[[2-(2-furanyl)-5-methyl-4-oxazolyl]methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441357-00-2 CAPLUS
CN 3-Pyridinecarboxaldehyde, 2-[[4-[[2-(2-furanyl)-5-methyl-4-oxazolyl]methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441357-01-3 CAPLUS
CN 3-Pyridinemethanol, 2-[[4-[[2-(2-furanyl)-5-methyl-4-oxazolyl]methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441357-02-4 CAPLUS
CN 3-Pyridineacetonitrile, 2-[[4-[[2-(2-furanyl)-5-methyl-4-oxazolyl]methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441357-13-7 CAPLUS
CN 3-Pyridinecarbonitrile, 6-methyl-2-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441357-14-8 CAPLUS
CN 3-Pyridinecarboxaldehyde, 6-methyl-2-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441357-16-0 CAPLUS
CN 3-Pyridineacetonitrile, 6-methyl-2-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441357-27-3 CAPLUS
CN Oxazole, 5-methyl-2-phenyl-4-[[4-(phenylmethoxy)phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 441357-28-4 CAPLUS
CN Phenol, 4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]- (9CI) (CA INDEX NAME)



RN 441357-31-9 CAPLUS
CN 3-Pyridinecarboxylic acid, 2-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenoxy]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 441357-32-0 CAPLUS
CN 3-Pyridinemethanol, 2-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 441357-33-1 CAPLUS
CN 3-Pyridineacetonitrile, 2-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 441357-43-3 CAPLUS
CN Benzenemethanol, 4-[[5-methyl-2-(2-naphthalenyl)-4-oxazolyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441357-44-4 CAPLUS
CN 3-Pyridinecarbonitrile, 2-[[4-[[5-methyl-2-(2-naphthalenyl)-4-oxazolyl]methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441357-45-5 CAPLUS
CN 3-Pyridinecarboxaldehyde, 2-[[4-[[5-methyl-2-(2-naphthalenyl)-4-oxazolyl]methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441357-46-6 CAPLUS
CN 3-Pyridinemethanol, 2-[[4-[[5-methyl-2-(2-naphthalenyl)-4-oxazolyl]methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441357-47-7 CAPLUS
CN 3-Pyridineacetonitrile, 2-[[4-[[5-methyl-2-(2-naphthalenyl)-4-oxazolyl]methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441357-49-9 CAPLUS
CN 3-Pyridinecarbonitrile, 2-[[4-[[2-(2-furanyl)-5-methyl-4-oxazolyl]methoxy]-3-methoxyphenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441357-50-2 CAPLUS
CN 3-Pyridinecarboxaldehyde, 2-[[4-[[2-(2-furanyl)-5-methyl-4-oxazolyl]methoxy]-3-methoxyphenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 441357-51-3 CAPLUS
CN Benzoic acid, 3-[[[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]thio]- (9CI) (CA INDEX NAME)



RN 441357-52-4 CAPLUS
CN Benzoic acid, 3-[[[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]thio]-, methyl ester (9CI) (CA INDEX NAME)



RN 441357-53-5 CAPLUS
CN Benzaldehyde, 3-[[[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]thio]- (9CI) (CA INDEX NAME)



RN 441357-54-6 CAPLUS
CN Propanedioic acid, [3-[[[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]thio]phenyl]-, monoethyl ester (9CI) (CA INDEX NAME)



RN 441357-55-7 CAPLUS
CN Benzeneacetonitrile, 3-[[[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]thio]- (9CI) (CA INDEX NAME)



RN 441357-56-8 CAPLUS

CN 3-Pyridinemethanesulfonic acid, α-hydroxy-2-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 441357-57-9 CAPLUS

CN Pyridine, 2-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-3-oxiranyl- (9CI) (CA INDEX NAME)



RN 441357-65-9 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-[[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-, methyl ester (9CI) (CA INDEX NAME)



```
REFERENCE COUNT:         11    THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21  ANSWER 2 OF 21  CAPLUS  COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER:        2002:466002  CAPLUS
DOCUMENT NUMBER:         137:33304
TITLE:                   Preparation of N-phenylalkylazole derivatives as HER2
                         inhibitors and medicinal compositions containing
                         microcrystalline particle suspension and powder of the
                         derivatives improved in oral absorbability
INVENTOR(S):             Nara, Eiji
PATENT ASSIGNEE(S):      Takeda Chemical Industries, Ltd., Japan
SOURCE:                  PCT Int. Appl., 141 pp.
                         CODEN: PIXXD2
DOCUMENT TYPE:           Patent
LANGUAGE:                Japanese
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

     PATENT NO.       KIND  DATE          APPLICATION NO.  DATE
     ---------------  ----  --------      ---------------  --------
     WO 2002048142     A1   20020620      WO 2001-JP10827  20011211 <--
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS,
             LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL,
             PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,
             UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
             CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     AU 2002021115     A5   20020624      AU 2002-21115    20011211 <--
     JP 2003026676     A2   20030129      JP 2001-377074   20011211
     EP 1350793        A1   20031008      EP 2001-270221   20011211
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
     US 2004053972     A1   20040318      US 2003-433720   20030604 <--
     NO 2003002614     A    20030805      NO 2003-2614     20030610
PRIORITY APPLN. INFO.:                 JP 2000-375608   A  20001211
                                       WO 2001-JP10827  W  20011211
OTHER SOURCE(S):         MARPAT 137:33304
GI
```



I



I

AB Disclosed are human epidermal growth factor receptor-2 protein (HER2) inhibitors having an average particle size of about 3 µm or less when they are dispersed in water, wherein HER2 inhibitors are N-phenylalkylazole derivs. [I; R = (un)substituted aromatic heterocyclyl; X = O, optionally oxidized S, CO, CH(OH); Y = CH, N; p = 0-10; q = 1-5; the ring B = (un)substituted aromatic azole group; the ring A is optionally substituted] or salts thereof or prodrugs thereof. Also disclosed are pharmaceutical compns. containing I and at least one stabilizer which is selected from (1) surfactants, (2) hydrophilic polymer, and (3) readily water-soluble cyclodextrin derivative These pharmaceutical compns. are administered p.o. and useful as anticancer agents for the treatment or prevention of breast cancer or prostate cancer. **Thus**, 152 mg 4-[4-(1H-1,2,3-triazol-1-yl)butyl]phenol and 28 mg NaH (60% in oil) were dissolved in 5 mL DMF, followed by adding 212 mg 4-(chloromethyl)-2-[(E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1,3-oxazole under ice-cooling, and the resulting mixture was stirred at room temperature for 3 h to give 290 mg 1-[4-[4-[[2-[(E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1,3-oxazol-4-yl]methoxy]phenyl]butyl]-1H-1,2,3-triazole (II). II in vitro showed IC50 of <0.05 µM µM for inhibiting the proliferation of human breast cancer BT-474 cells and in vivo at 30 mg/kg per day for 10 days inhibited the proliferation of human breast cancer BT-474 cells transplanted in Balb/C female nude mice. A mixture of II 1,000, sodium deoxycholate 1,000, and hydroxypropyl cellulose 1,000 mg was pulverized by a ball mill at room temperature for 2 h, treated with 80 mL distilled water, and was treated by ultrasound under ice-cooling for 30 min, and then the resulting suspension was further homogenized by a high pressure homogenizer (Micronlab 40, AVP Gaulin GmbH) at 1,500 bar eight-times to give a microcryst. suspension which improved three-times the oral absorbability in rats.

IT **366017-06-3P 366017-07-4P 366017-08-5P**
366017-09-6P 366017-10-9P 366017-11-0P
366017-12-1P 366017-13-2P 366017-14-3P
366017-15-4P 366017-16-5P 366017-18-7P
366017-20-1P 366017-22-3P 366017-23-4P
366017-25-6P 366017-26-7P 366017-27-8P
366017-28-9P 366017-30-3P 366017-32-5P
366017-33-6P 366017-34-7P 366017-35-8P
366017-37-0P 366017-39-2P 366017-41-6P
436099-70-6P 436099-72-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-phenylalkylazole derivs. as HER2 inhibitors and microcryst. particle suspension and powder containing them with improved

oral absorbability)

RN 366017-06-3 CAPLUS

CN 1H-1,2,3-Triazole, 1-[4-[4-[[2-[(1E)-2-(4-methylphenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-07-4 CAPLUS

CN 1H-1,2,3-Triazole, 1-[4-[4-[[2-[(1E)-2-(4-fluorophenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-08-5 CAPLUS

CN 1H-1,2,3-Triazole, 1-[3-[3-[[2-[(1E)-2-(4-fluorophenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-09-6 CAPLUS

CN 1H-1,2,3-Triazole, 1-[4-[4-[[2-[(1E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-10-9 CAPLUS
CN 1H-1,2,3-Triazole, 1-[3-[4-[[2-[(1E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-4-oxazolyl]methoxy]phenyl]propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-11-0 CAPLUS
CN 1H-1,2,3-Triazole, 1-[3-[3-[[2-[(1E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-4-oxazolyl]methoxy]phenyl]propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-12-1 CAPLUS
CN 1H-1,2,3-Triazole, 1-[4-[4-[[2-[(1E)-2-(2,4-difluorophenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-13-2 CAPLUS
CN 1H-1,2,3-Triazole, 1-[3-[3-[[2-[(1E)-2-(2,4-difluorophenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-14-3 CAPLUS
CN 1H-1,2,3-Triazole, 1-[4-[4-[[2-[(1E)-2-(2,6-difluorophenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-15-4 CAPLUS
CN 1H-Imidazole-2-ethanol, 1-[4-[4-[[2-[(1E)-2-(4-methylphenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-16-5 CAPLUS
CN 1H-Imidazole-2-ethanol, 1-[4-[4-[[2-[(1E)-2-(3-methylphenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-18-7 CAPLUS
CN 1H-Imidazole-2-ethanol, 1-[4-[4-[[2-[(1E)-2-(2-methylphenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-20-1 CAPLUS
CN 1H-Imidazole-2-ethanol, 1-[4-[4-[[2-[(1E)-2-(4-ethylphenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-22-3 CAPLUS
CN 1H-Imidazole-2-ethanol, 1-[4-[4-[[2-[(1E)-2-(4-fluorophenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-23-4 CAPLUS
CN 1H-Imidazole-2-ethanol, 1-[4-[4-[[2-[(1E)-2-(4-chlorophenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-25-6 CAPLUS
CN 1H-Imidazole-2-ethanol, 1-[4-[4-[[2-[(1E)-2-(4-bromophenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-26-7 CAPLUS
CN 1H-Imidazole-2-ethanol, 1-[4-[4-[[2-[(1E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-27-8 CAPLUS
CN 1H-Imidazole-2-ethanol, 1-[3-[4-[[2-[(1E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-4-oxazolyl]methoxy]phenyl]propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-28-9 CAPLUS
CN 1H-Imidazole-2-ethanol, 1-[4-[4-[[2-[(1E)-2-(2,4-difluorophenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-30-3 CAPLUS
CN 1H-Imidazole-2-ethanol, 1-[3-[4-[[2-[(1E)-2-(2,4-difluorophenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-32-5 CAPLUS
CN 1H-Imidazole-2-ethanol, 1-[3-[4-[[2-[(1E)-2-(2,6-difluorophenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-33-6 CAPLUS
CN 1,2-Propanediol, 3-[1-[4-[4-[[2-[(1E)-2-(3-methylphenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-34-7 CAPLUS
CN 1,2-Propanediol, 3-[1-[4-[4-[[2-[(1E)-2-(4-fluorophenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-35-8 CAPLUS
CN 1,2-Propanediol, 3-[1-[4-[4-[[2-[(1E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 366017-37-0 CAPLUS

CN 1,2-Propanediol, 3-[1-[4-[4-[[2-[(1E)-2-(2,4-difluorophenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-39-2 CAPLUS

CN 1,2-Propanediol, 3-[1-[4-[4-[[2-[(1E)-2-(2,6-difluorophenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-41-6 CAPLUS
CN 1,2-Propanediol, 3-[1-[4-[4-[[2-[(1E)-2-(2,4-difluorophenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]-1H-imidazol-2-yl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 436099-70-6 CAPLUS
CN 1,2-Propanediol, 3-[1-[3-[3-[[2-[(1E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-4-oxazolyl]methoxy]phenyl]propyl]-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 436099-72-8 CAPLUS
CN 1,2-Propanediol, 3-[1-[3-[3-[[2-[(1E)-2-(2,4-difluorophenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]propyl]-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **366017-00-7P 366017-01-8P 366017-03-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-phenylalkylazole derivs. as HER2 inhibitors and microcryst. particle suspension and powder containing them with improved oral absorbability)
RN 366017-00-7 CAPLUS
CN Oxazole, 2-[(1E)-2-(2,4-difluorophenyl)ethenyl]-4-[[4-(4-iodobutyl)phenoxy]methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-01-8 CAPLUS
CN Benzenebutanol, 4-[[2-[(1E)-2-(2,4-difluorophenyl)ethenyl]-4-oxazolyl]methoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-03-0 CAPLUS
CN Oxazole, 2-[(1E)-2-(4-bromophenyl)ethenyl]-4-[[4-(4-iodobutyl)phenoxy]methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 3 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:466001 CAPLUS
DOCUMENT NUMBER: 137:33303
TITLE: Preparation of N-phenylalkylazole derivatives as HER2 inhibitors and medicinal compositions improved in solubility in water
INVENTOR(S): Akiyama, Yohko; Iinuma, Satoshi; Bando, Hiroto
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 147 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

```
     PATENT NO.        KIND  DATE           APPLICATION NO.   DATE
     ---------------   ----  --------       ---------------   --------
     WO 2002048141      A1   20020620       WO 2001-JP10768   20011210 <--
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS,
             LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL,
             PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,
             UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
             CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     AU 2002021096      A5   20020624       AU 2002-21096     20011210 <--
     JP 2002241268      A2   20020828       JP 2001-375573    20011210 <--
     EP 1350792         A1   20031008       EP 2001-270217    20011210
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
     US 2004058956      A1   20040325       US 2003-433507    20030603 <--
     NO 2003002613     A    20030805        NO 2003-2613       20030610
PRIORITY APPLN. INFO.:                      JP 2000-375601   A 20001211
                                            WO 2001-JP10768  W 20011210
OTHER SOURCE(S):            MARPAT 137:33303
GI
```



I



I

AB Disclosed are solid dispersions containing human epidermal growth factor receptor-2 protein (HER2) inhibitors, i.e. N-phenylalkylazole derivs. [I; R = (un)substituted aromatic heterocyclyl; X = O, optionally oxidized S, CO, CH(OH); Y = CH, N; p = 0-10; q = 1-5; the ring B = (un)substituted aromatic azole group; the ring A is optionally substituted], which are hardly or not soluble in water, and a hydrophilic polymer. The hydrophilic polymer is enteric polymer which is selected from cellulose derivative, polyalkenylpyrrolidone, polyalkylene glycol, or methacrylic acid copolymer. These solid dispersions have been improved in the solubility of the HER2 inhibitors, oral absorbability and absorbability in blood.
Thus, 152 mg 4-[4-(1H-1,2,3-triazol-1-yl)butyl]phenol and 28 mg NaH (60% in oil) were dissolved in 5 mL DMF, followed by adding 212 mg 4-(chloromethyl)-2-[(E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1,3-oxazole under ice-cooling, and the resulting mixture was stirred at room temperature for 3 h to give 290 mg 1-[4-[4-[[2-[(E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1,3-oxazol-4-yl]methoxy]phenyl]butyl]-1H-1,2,3-triazole (II). II in vitro showed IC50 of <0.05 µM µM for inhibiting the proliferation of human breast cancer BT-474 cells and in vivo at 30 mg/kg per day for 10 days inhibited the proliferation of human breast cancer BT-474 cells transplanted in Balb/C female nude mice. II (0.1 g) was dissolved in 10 mL CH2Cl2, followed by adding and dissolving 0.8 g polyvinylpyrrolidone (K-30, Wako Pure Chemical Industries, Ltd., Japan), adding and dispersing 0.1 g lactose to homogeneity, and distilling off the solvent, the residue was dried by a vacuum dryer under reduced pressure for 14 h and pulverized by a ball mill for 90 min to give a solid dispersion (0.55 g) of II. The above dispersion was used to formulate tablets.

IT **366017-06-3P**, 1-[4-[4-[[2-[(E)-2-(4-Methylphenyl)ethenyl]-1,3-oxazol-4-yl]methoxy]phenyl]butyl]-1H-1,2,3-triazole **366017-07-4P**, 1-[4-[4-([2-[(E)-2-(4-Fluorophenyl)ethenyl]-1,3-oxazol-4-yl]methoxy)phenyl]butyl]-1H-1,2,3-triazole **366017-08-5P**, 1-[3-[3-([2-[(E)-2-(4-Fluorophenyl)ethenyl]-1,3-oxazol-4-yl]methoxy)phenyl]propyl]-1H-1,2,3-triazole **366017-09-6P**, 1-(4-[4-[(2-[(E)-2-[4-(Trifluoromethyl)phenyl]ethenyl]-1,3-oxazol-4-yl)methoxy]phenyl]butyl)-1H-1,2,3-triazole **366017-10-9P**,

1-(3-[4-[(2-[(E)-2-[4-(Trifluoromethyl)phenyl]ethenyl]-1,3-oxazol-4-
yl)methoxy]phenyl]propyl)-1H-1,2,3-triazole **366017-11-0P**,
1-(3-[3-[(2-[(E)-2-[4-(Trifluoromethyl)phenyl]ethenyl]-1,3-oxazol-4-
yl)methoxy]phenyl]propyl)-1H-1,2,3-triazole **366017-12-1P**,
1-[4-[4-([2-[(E)-2-(2,4-Difluorophenyl)ethenyl]-1,3-oxazol-4-
yl]methoxy)phenyl]butyl]-1H-1,2,3-triazole **366017-13-2P**,
1-[3-[3-([2-[(E)-2-(2,4-Difluorophenyl)ethenyl]-1,3-oxazol-4-
yl]methoxy)phenyl]propyl]-1H-1,2,3-triazole **366017-14-3P**,
1-[4-[4-[[2-[(E)-2-(2,6-Difluorophenyl)ethenyl]-1,3-oxazol-4-
yl]methoxy]phenyl]butyl]-1H-1,2,3-triazole **366017-15-4P**,
2-[1-[4-[4-[[2-[(E)-2-(4-Methylphenyl)ethenyl]-1,3-oxazol-4-
yl]methoxy]phenyl]butyl]-1H-imidazol-2-yl]-1-ethanol **366017-16-5P**
, 2-[1-[4-[4-[[2-[(E)-2-(3-Methylphenyl)ethenyl]-1,3-oxazol-4-
yl]methoxy]phenyl]butyl]-1H-imidazol-2-yl]-1-ethanol **366017-18-7P**
, 2-[1-[4-[4-[[2-[(E)-2-(2-Methylphenyl)ethenyl]-1,3-oxazol-4-
yl]methoxy]phenyl]butyl]-1H-imidazol-2-yl]-1-ethanol **366017-20-1P**
, 2-[1-[4-[4-[[2-[(E)-2-(4-Ethylphenyl)ethenyl]-1,3-oxazol-4-
yl]methoxy]phenyl]butyl]-1H-imidazol-2-yl]-1-ethanol **366017-22-3P**
, 2-(1-[4-[4-([2-[(E)-2-(4-Fluorophenyl)ethenyl]-1,3-oxazol-4-
yl]methoxy)phenyl]butyl]-1H-imidazol-2-yl)-1-ethanol **366017-23-4P**
, 2-[1-[4-[4-[[2-[(E)-2-(4-Chlorophenyl)ethenyl]-1,3-oxazol-4-
yl]methoxy]phenyl]butyl]-1H-imidazol-2-yl]-1-ethanol **366017-25-6P**
, 2-[1-[4-[4-[[2-[(E)-2-(4-Bromophenyl)ethenyl]-1,3-oxazol-4-
yl]methoxy]phenyl]butyl]-1H-imidazol-2-yl]-1-ethanol **366017-26-7P**
366017-27-8P **366017-28-9P**, 2-[1-[4-[4-[[2-[(E)-2-(2,4-
Difluorophenyl)ethenyl]-1,3-oxazol-4-yl]methoxy]phenyl]butyl]-1H-imidazol-
2-yl]-1-ethanol **366017-30-3P**, 2-[1-[3-[4-[[2-[(E)-2-(2,4-
Difluorophenyl)ethenyl]-1,3-oxazol-4-yl]methoxy]phenyl]propyl]-1H-imidazol-
2-yl]-1-ethanol **366017-32-5P**, 2-[1-[3-[4-[[2-[(E)-2-(2,6-
Difluorophenyl)ethenyl]-1,3-oxazol-4-yl]methoxy]phenyl]propyl]-1H-imidazol-
2-yl]-1-ethanol **366017-33-6P**, 3-(1-[4-[4-([2-[(E)-2-(3-
Methylphenyl)ethenyl]-1,3-oxazol-4-yl]methoxy)phenyl]butyl]-1H-imidazol-2-
yl)-1,2-propanediol **366017-34-7P**, 3-(1-[4-[4-([2-[(E)-2-(4-
Fluorophenyl)ethenyl]-1,3-oxazol-4-yl]methoxy)phenyl]butyl]-1H-imidazol-2-
yl)-1,2-propanediol **366017-35-8P**, 3-[1-(4-[4-[(2-[(E)-2-[4-
(Trifluoromethyl)phenyl]ethenyl]-1,3-oxazol-4-yl)methoxy]phenyl]butyl)-1H-
imidazol-2-yl]-1,2-propanediol **366017-37-0P**,
3-(1-[4-[4-([2-[(E)-2-(2,4-Difluorophenyl)ethenyl]-1,3-oxazol-4-
yl]methoxy)phenyl]butyl]-1H-imidazol-2-yl)-1,2-propanediol
366017-39-2P, 3-[1-[4-[4-[[2-[(E)-2-(2,6-Difluorophenyl)ethenyl]-
1,3-oxazol-4-yl]methoxy]phenyl]butyl]-1H-imidazol-2-yl]-1,2-propanediol
366017-41-6P **436099-70-6P**, 3-[1-(3-[3-[(2-[(E)-2-[4-
(Trifluoromethyl)phenyl]ethenyl]-1,3-oxazol-4-yl)methoxy]phenyl]propyl)-1H-
imidazol-2-yl]-1,2-propanediol **436099-72-8P**,
3-(1-[3-[3-([2-[(E)-2-(2,4-Difluorophenyl)ethenyl]-1,3-oxazol-4-
yl]methoxy)phenyl]propyl]-1H-imidazol-2-yl)-1,2-propanediol
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(preparation of N-phenylalkylazole derivs. as HER2 inhibitors and solid
dispersions containing them with improved solubility in water)

RN 366017-06-3 CAPLUS

CN 1H-1,2,3-Triazole, 1-[4-[4-[[2-[(1E)-2-(4-methylphenyl)ethenyl]-4-
oxazolyl]methoxy]phenyl]butyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-07-4 CAPLUS
CN 1H-1,2,3-Triazole, 1-[4-[4-[[2-[(1E)-2-(4-fluorophenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-08-5 CAPLUS
CN 1H-1,2,3-Triazole, 1-[3-[3-[[2-[(1E)-2-(4-fluorophenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-09-6 CAPLUS
CN 1H-1,2,3-Triazole, 1-[4-[4-[[2-[(1E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-10-9 CAPLUS
CN 1H-1,2,3-Triazole, 1-[3-[4-[[2-[(1E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-4-oxazolyl]methoxy]phenyl]propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-11-0 CAPLUS
CN 1H-1,2,3-Triazole, 1-[3-[3-[[2-[(1E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-4-oxazolyl]methoxy]phenyl]propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-12-1 CAPLUS
CN 1H-1,2,3-Triazole, 1-[4-[4-[[2-[(1E)-2-(2,4-difluorophenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-13-2 CAPLUS
CN 1H-1,2,3-Triazole, 1-[3-[3-[[2-[(1E)-2-(2,4-difluorophenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-14-3 CAPLUS
CN 1H-1,2,3-Triazole, 1-[4-[4-[[2-[(1E)-2-(2,6-difluorophenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-15-4 CAPLUS

CN 1H-Imidazole-2-ethanol, 1-[4-[4-[[2-[(1E)-2-(4-methylphenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-16-5 CAPLUS

CN 1H-Imidazole-2-ethanol, 1-[4-[4-[[2-[(1E)-2-(3-methylphenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-18-7 CAPLUS

CN 1H-Imidazole-2-ethanol, 1-[4-[4-[[2-[(1E)-2-(2-methylphenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-20-1 CAPLUS
CN 1H-Imidazole-2-ethanol, 1-[4-[4-[[2-[(1E)-2-(4-ethylphenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-22-3 CAPLUS
CN 1H-Imidazole-2-ethanol, 1-[4-[4-[[2-[(1E)-2-(4-fluorophenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-23-4 CAPLUS
CN 1H-Imidazole-2-ethanol, 1-[4-[4-[[2-[(1E)-2-(4-chlorophenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-25-6 CAPLUS
CN 1H-Imidazole-2-ethanol, 1-[4-[4-[[2-[(1E)-2-(4-bromophenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-26-7 CAPLUS
CN 1H-Imidazole-2-ethanol, 1-[4-[4-[[2-[(1E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-27-8 CAPLUS
CN 1H-Imidazole-2-ethanol, 1-[3-[4-[[2-[(1E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-4-oxazolyl]methoxy]phenyl]propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-28-9 CAPLUS
CN 1H-Imidazole-2-ethanol, 1-[4-[4-[[2-[(1E)-2-(2,4-difluorophenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-30-3 CAPLUS
CN 1H-Imidazole-2-ethanol, 1-[3-[4-[[2-[(1E)-2-(2,4-difluorophenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-32-5 CAPLUS
CN 1H-Imidazole-2-ethanol, 1-[3-[4-[[2-[(1E)-2-(2,6-difluorophenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-33-6 CAPLUS
CN 1,2-Propanediol, 3-[1-[4-[4-[[2-[(1E)-2-(3-methylphenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-34-7 CAPLUS
CN 1,2-Propanediol, 3-[1-[4-[4-[[2-[(1E)-2-(4-fluorophenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-35-8 CAPLUS
CN 1,2-Propanediol, 3-[1-[4-[4-[[2-[(1E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 366017-37-0 CAPLUS

CN 1,2-Propanediol, 3-[1-[4-[4-[[2-[(1E)-2-(2,4-difluorophenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-39-2 CAPLUS

CN 1,2-Propanediol, 3-[1-[4-[4-[[2-[(1E)-2-(2,6-difluorophenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-41-6 CAPLUS
CN 1,2-Propanediol, 3-[1-[4-[4-[[2-[(1E)-2-(2,4-difluorophenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]-1H-imidazol-2-yl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 436099-70-6 CAPLUS
CN 1,2-Propanediol, 3-[1-[3-[3-[[2-[(1E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-4-oxazolyl]methoxy]phenyl]propyl]-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 436099-72-8 CAPLUS
CN 1,2-Propanediol, 3-[1-[3-[3-[[2-[(1E)-2-(2,4-difluorophenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]propyl]-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **366017-00-7P**, 2-[(E)-2-(2,4-Difluorophenyl)ethenyl]-4-[[4-(4-iodobutyl)phenoxy]methyl]-1,3-oxazole **366017-01-8P** **366017-03-0P**, 2-[(E)-2-(4-Bromophenyl)ethenyl]-4-[[4-(4-iodobutyl)phenoxy]methyl]-1,3-oxazole
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-phenylalkylazole derivs. as HER2 inhibitors and solid dispersions containing them with improved solubility in water)
RN 366017-00-7 CAPLUS
CN Oxazole, 2-[(1E)-2-(2,4-difluorophenyl)ethenyl]-4-[[4-(4-iodobutyl)phenoxy]methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-01-8 CAPLUS
CN Benzenebutanol, 4-[[2-[(1E)-2-(2,4-difluorophenyl)ethenyl]-4-oxazolyl]methoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-03-0 CAPLUS
CN Oxazole, 2-[(1E)-2-(4-bromophenyl)ethenyl]-4-[[4-(4-iodobutyl)phenoxy]methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 4 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:72064 CAPLUS
DOCUMENT NUMBER: 136:118452
TITLE: Method for producing 1-substituted-1,2,3-triazole derivatives
INVENTOR(S): Ikemoto, Tomomi; Ito, Tatsuya; Tomimatsu, Kiminori; Sawai, Yasuhiro; Nishiyama, Hirohiko; Isogami, Yasushi
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 170 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

```
     PATENT NO.        KIND  DATE           APPLICATION NO.   DATE
     ---------------   ----  --------       ---------------   --------
     WO 2002006249      A1   20020124       WO 2001-JP6145    20010716 <--
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS,
             LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,
             RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,
             VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     AU 2001071058      A5   20020130       AU 2001-71058     20010716 <--
     EP 1310491         A1   20030514       EP 2001-950000    20010716
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
     JP 2003048882      A2    20030221        JP 2001-218718    20010718
     US 2003069419      A1    20030410        US 2002-19264     20020419 <--
PRIORITY APPLN. INFO.:                     JP 2000-218814   A  20000719
                                           JP 2000-218834   A  20000719
                                           JP 2000-284925   A  20000920
                                           JP 2001-160464   A  20010529
                                           WO 2001-JP6145   W  20010716
OTHER SOURCE(S):           CASREACT 136:118452; MARPAT 136:118452
GI
```



I

AB The title compds., e.g. I [R1, R2 = H, (un)substituted hydrocarbon group, etc.; R3 = R6(CR4R5)m; R4, R5 = H, (un)substituted hydrocarbon group, etc.; R6 = (un)substituted aromatic moiety; m = 0 - 10; R7 , R8 = H, halo, etc.], are prepared by reacting R1C(R2)(R3)X [X = leaving group] with appropriate triazole derivs. (a) in a secondary or tertiary alc. in the presence of a base or (b) in the absence of a base. **Thus**, a mixture of 1-(4-chlorobutyl)-4-methoxybenzene, 1H-1,2,3-triazole, potassium iodide, and sodium hydroxide in tert-butanol was refluxed for 11 h to give, after workup and treatment with methanesulfonic acid, 1-[4-(4-methoxyphenyl)butan-1-yl]-1H-1,2,3-triazole methanesulfonic acid salt (II) in 73% yield. II is an intermediate in the preparation of 1-[4-[4-[[2-[((E)-2-(4-trifluoromethyl)phenyl)ethenyl]-1,3-oxazol-4-yl]methoxy]phenyl]butyl]-1H-1,2,3-triazole (III), useful as a tyrosine kinase inhibitor (no data). A pharmaceutical composition containing crystals of III is claimed.

IT **366017-09-6P**

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(method for producing triazole derivs.)

RN 366017-09-6 CAPLUS

CN 1H-1,2,3-Triazole, 1-[4-[4-[[2-[(1E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **391202-04-3P 391202-06-5P 391202-08-7P**

391202-10-1P
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(method for producing triazole derivs.)

RN 391202-04-3 CAPLUS
CN 1H-1,2,3-Triazole, 1-[4-[4-[[2-[(1E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 366017-09-6
CMF C25 H23 F3 N4 O2

Double bond geometry as shown.



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 391202-06-5 CAPLUS
CN 1H-1,2,3-Triazole, 1-[4-[4-[[2-[(1E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 391202-08-7 CAPLUS
CN 1H-1,2,3-Triazole, 1-[4-[4-[[2-[(1E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]-, monobenzenesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 366017-09-6
CMF C25 H23 F3 N4 O2

Double bond geometry as shown.



CM 2

CRN 98-11-3
CMF C6 H6 O3 S



RN 391202-10-1 CAPLUS
CN 1H-1,2,3-Triazole, 1-[4-[4-[[2-[(1E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 366017-09-6
CMF C25 H23 F3 N4 O2

Double bond geometry as shown.



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



IT **391202-33-8P**
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(triazole derivs.)
RN 391202-33-8 CAPLUS
CN 1H-1,2,3-Triazole, 1-[4-[4-[[2-[(1E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]-, sulfate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 366017-09-6
CMF C25 H23 F3 N4 O2

Double bond geometry as shown.



CM 2

CRN 7664-93-9
CMF H2 O4 S



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 5 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:762995 CAPLUS
DOCUMENT NUMBER: 135:303897
TITLE: Preparation of 2-styryl-4-(phenoxymethyl)oxazole derivatives as tyrosine kinase inhibitors
INVENTOR(S): Tasaka, Akihiro; Hitaka, Takenori; Matsutani, Etsuya
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan

```
SOURCE:                      PCT Int. Appl., 125 pp.
                             CODEN: PIXXD2
DOCUMENT TYPE:               Patent
LANGUAGE:                    English
FAMILY ACC. NUM. COUNT:      1
PATENT INFORMATION:

     PATENT NO.          KIND  DATE              APPLICATION NO.  DATE
     ---------------     ----  --------          ---------------  --------
     WO 2001077107        A1   20011018          WO 2001-JP2937   20010405 <--
     WO 2001077107        C1   20030213
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
             HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT,
             LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
             SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
             YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     AU 2001044726        A5   20011023          AU 2001-44726    20010405 <--
     EP 1268473           A1   20030102          EP 2001-917827   20010405
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
     BR 2001009851        A    20030603          BR 2001-9851     20010405
     JP 2001348385        A2   20011218          JP 2001-108204   20010406 <--
     JP 3273777           B2   20020415
     JP 2002069070        A2   20020308          JP 2001-212773   20010406 <--
     US 2002173526        A1   20021121          US 2001-889974   20010724 <--
     US 6716863           B2   20040406
     NO 2002004742        A    20021125          NO 2002-4742     20021002 <--
     US 2004024035        A1   20040205          US 2003-620706   20030717 <--
PRIORITY APPLN. INFO.:                       JP 2000-106836   A  20000407
                                             WO 2001-JP2937   W  20010405
                                             JP 2001-108204   A3 20010406
                                             US 2001-889974   A3 20010724
OTHER SOURCE(S):             CASREACT 135:303897; MARPAT 135:303897
GI
```



I

Q =



Q1 =



AB Compds. represented by formula (I; wherein m is 1 or 2; R1 is a halogen or an optionally halogenated C1-2 alkyl; one of R2 and R3 is a hydrogen atom and the other is a group represented by formula Q or Q1, wherein n is 3 or 4; R4 is a C1-4 alkyl group substituted by 1 or 2 hydroxy groups) or salts thereof are prepared These compds. are useful for preventing or treating cancer, in particular breast, prostate, and lung cancer and also are used in combination with a LH-RH modulator such as leuprorelin which is a LH-RH antagonist. **Thus**, 4-(chloromethyl)-2-[(E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1,3-oxazole was added to a solution of 4-[4-(1H-1,2,3-triazol-1-yl)butyl]phenol and NaH in DMF under ice cooling and stirred at room temperature for 3 h to give 1-[4-[4-[[2-[(E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1,3-oxazol-4-yl]methoxy]phenyl]butyl]-1H-1,2,3-triazole (II). II potently inhibited the phosphorylation reaction of the tyrosine residue of the HER2 receptor protein of the growth factor heregulin in human breast cancer MCF-7 cells with IC50 of 0.10 μM. Tablet formulations containing II were described.

IT **366017-00-7P 366017-01-8P 366017-03-0P**
366017-05-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of 2-styryl(phenoxymethyl)oxazole derivs. as tyrosine kinase inhibitors for preventing or treating cancers)

RN 366017-00-7 CAPLUS

CN Oxazole, 2-[(1E)-2-(2,4-difluorophenyl)ethenyl]-4-[[4-(4-iodobutyl)phenoxy]methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-01-8 CAPLUS
CN Benzenebutanol, 4-[[2-[(1E)-2-(2,4-difluorophenyl)ethenyl]-4-oxazolyl]methoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-03-0 CAPLUS
CN Oxazole, 2-[(1E)-2-(4-bromophenyl)ethenyl]-4-[[4-(4-iodobutyl)phenoxy]methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-05-2 CAPLUS
CN Benzenebutanol, 4-[[2-[(1E)-2-(4-bromophenyl)ethenyl]-4-oxazolyl]methoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **366017-06-3P 366017-07-4P 366017-08-5P**
366017-09-6P 366017-10-9P 366017-11-0P
366017-12-1P 366017-13-2P 366017-14-3P
366017-15-4P 366017-16-5P 366017-18-7P
366017-20-1P 366017-22-3P 366017-23-4P

366017-25-6P 366017-26-7P 366017-27-8P
366017-28-9P 366017-30-3P 366017-32-5P
366017-33-6P 366017-34-7P 366017-35-8P
366017-36-9P 366017-37-0P 366017-38-1P
366017-39-2P 366017-40-5P 366017-41-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-styryl(phenoxymethyl)oxazole derivs. as tyrosine kinase inhibitors for preventing or treating cancers)

RN 366017-06-3 CAPLUS
CN 1H-1,2,3-Triazole, 1-[4-[4-[[2-[(1E)-2-(4-methylphenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-07-4 CAPLUS
CN 1H-1,2,3-Triazole, 1-[4-[4-[[2-[(1E)-2-(4-fluorophenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-08-5 CAPLUS
CN 1H-1,2,3-Triazole, 1-[3-[3-[[2-[(1E)-2-(4-fluorophenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-09-6 CAPLUS
CN 1H-1,2,3-Triazole, 1-[4-[4-[[2-[(1E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-10-9 CAPLUS
CN 1H-1,2,3-Triazole, 1-[3-[4-[[2-[(1E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-4-oxazolyl]methoxy]phenyl]propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-11-0 CAPLUS
CN 1H-1,2,3-Triazole, 1-[3-[3-[[2-[(1E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-4-oxazolyl]methoxy]phenyl]propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-12-1 CAPLUS
CN 1H-1,2,3-Triazole, 1-[4-[4-[[2-[(1E)-2-(2,4-difluorophenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-13-2 CAPLUS
CN 1H-1,2,3-Triazole, 1-[3-[3-[[2-[(1E)-2-(2,4-difluorophenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-14-3 CAPLUS
CN 1H-1,2,3-Triazole, 1-[4-[4-[[2-[(1E)-2-(2,6-difluorophenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-15-4 CAPLUS
CN 1H-Imidazole-2-ethanol, 1-[4-[4-[[2-[(1E)-2-(4-methylphenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-16-5 CAPLUS
CN 1H-Imidazole-2-ethanol, 1-[4-[4-[[2-[(1E)-2-(3-methylphenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-18-7 CAPLUS
CN 1H-Imidazole-2-ethanol, 1-[4-[4-[[2-[(1E)-2-(2-methylphenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-20-1 CAPLUS
CN 1H-Imidazole-2-ethanol, 1-[4-[4-[[2-[(1E)-2-(4-ethylphenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-22-3 CAPLUS
CN 1H-Imidazole-2-ethanol, 1-[4-[4-[[2-[(1E)-2-(4-fluorophenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-23-4 CAPLUS
CN 1H-Imidazole-2-ethanol, 1-[4-[4-[[2-[(1E)-2-(4-chlorophenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-25-6 CAPLUS
CN 1H-Imidazole-2-ethanol, 1-[4-[4-[[2-[(1E)-2-(4-bromophenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-26-7 CAPLUS
CN 1H-Imidazole-2-ethanol, 1-[4-[4-[[2-[(1E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-27-8 CAPLUS
CN 1H-Imidazole-2-ethanol, 1-[3-[4-[[2-[(1E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-4-oxazolyl]methoxy]phenyl]propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-28-9 CAPLUS
CN 1H-Imidazole-2-ethanol, 1-[4-[4-[[2-[(1E)-2-(2,4-difluorophenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-30-3 CAPLUS
CN 1H-Imidazole-2-ethanol, 1-[3-[4-[[2-[(1E)-2-(2,4-difluorophenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-32-5 CAPLUS
CN 1H-Imidazole-2-ethanol, 1-[3-[4-[[2-[(1E)-2-(2,6-difluorophenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-33-6 CAPLUS
CN 1,2-Propanediol, 3-[1-[4-[4-[[2-[(1E)-2-(3-methylphenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-34-7 CAPLUS
CN 1,2-Propanediol, 3-[1-[4-[4-[[2-[(1E)-2-(4-fluorophenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-35-8 CAPLUS
CN 1,2-Propanediol, 3-[1-[4-[4-[[2-[(1E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 366017-36-9 CAPLUS
CN 1,2-Propanediol, 3-[1-[3-[4-[[2-[(1E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-4-oxazolyl]methoxy]phenyl]propyl]-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 366017-37-0 CAPLUS
CN 1,2-Propanediol, 3-[1-[4-[4-[[2-[(1E)-2-(2,4-difluorophenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-38-1 CAPLUS
CN 1,2-Propanediol, 3-[1-[3-[4-[[2-[(1E)-2-(2,4-difluorophenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]propyl]-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-39-2 CAPLUS
CN 1,2-Propanediol, 3-[1-[4-[4-[[2-[(1E)-2-(2,6-difluorophenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 366017-40-5 CAPLUS
CN 1,2-Propanediol, 3-[1-[4-[4-[[2-[(1E)-2-(2,4-difluorophenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]-1H-imidazol-2-yl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 366017-41-6 CAPLUS
CN 1,2-Propanediol, 3-[1-[4-[4-[[2-[(1E)-2-(2,4-difluorophenyl)ethenyl]-4-oxazolyl]methoxy]phenyl]butyl]-1H-imidazol-2-yl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 6 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:	2001:257993 CAPLUS
DOCUMENT NUMBER:	134:280850
TITLE:	Preparation of aminothiazolidinediones for treatment of insulin resistance and hyperglycemia
INVENTOR(S):	Malamas, Michael S.; Gunawan, Iwan
PATENT ASSIGNEE(S):	USA
SOURCE:	U.S., 10 pp. CODEN: USXXAM
DOCUMENT TYPE:	**Patent**
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6214842	B1	20010410	US 2000-568832	20000511 <--

PRIORITY APPLN. INFO.: US 1999-219327P P 19990512
OTHER SOURCE(S): MARPAT 134:280850
GI



I

AB Title compds. [I; R = H, alkyl; A = (substituted) Ph, naphthyl, biphenyl], were prepared for treating or inhibiting type II diabetes (no data). **Thus**, 4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]aniline (preparation given), 5-bromothiazolidine-2,4-dione, and Et_3N were stirred 20 min. in DMF to give 70% 5-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenylamino]thiazolidine-2,4-dione.

IT **332899-82-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminothiazolidinediones for treatment of insulin resistance and hyperglycemia)

RN 332899-82-8 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[4'-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]methoxy][1,1'-biphenyl]-3-yl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 7 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:117035 CAPLUS
DOCUMENT NUMBER: 132:151814
TITLE: Preparation of substituted oxazoles and thiazoles as hPPAR gamma and hPPAR alpha activators
INVENTOR(S): Collins, Jon Loren; Dezube, Milana; Oplinger, Jeffrey Alan; Willson, Timothy Mark
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 110 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**

```
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

     PATENT NO.          KIND  DATE          APPLICATION NO.   DATE
     ---------------     ----  --------      ---------------   --------
     WO 2000008002        A1   20000217      WO 1999-EP5666    19990805 <--
         W:  AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
             CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN,
             IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG,
             MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,
             TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG,
             KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
             ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
             CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     CA 2339773           AA   20000217      CA 1999-2339773   19990805 <--
     AU 9957310           A1   20000228      AU 1999-57310     19990805 <--
     EP 1102757           A1   20010530      EP 1999-944335    19990805 <--
     EP 1102757           B1   20040414
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO
     TR 200100372         T2   20010921      TR 2001-20010037219990805 <--
     BR 9912866           A    20011030      BR 1999-12866     19990805 <--
     EE 200100074         A    20020617      EE 2001-74        19990805 <--
     AT 264313            E    20040415      AT 1999-944335    19990805
     ZA 2001000983        A    20020305      ZA 2001-983       20010205 <--
     NO 2001000628        A    20010406      NO 2001-628       20010206 <--
     HR 2001000095        A1   20020228      HR 2001-95        20010207 <--
     US 6498174           B1   20021224      US 2001-762445    20010222 <--
PRIORITY APPLN. INFO.:                       GB 1998-17118   A 19980807
                                             WO 1999-EP5666  W 19990805
OTHER SOURCE(S):         MARPAT 132:151814
GI
```



I

AB The title compds. [I; R1 = H, alkyl; R2 = H, alkyl, haloalkyl; R3 = alkyl, cycloalkyl, cycloalkenyl, etc.; R4 = (un)substituted 5-6 membered heterocyclyl containing at least one O, N or S atom, Ph; R5 = H, halo, alkyl, haloalkyl; R6 = H, alkyl; X = O, S; n = 1-3], which are dual activators of hPPARγ and hPPARα, were prepared **Thus**, refluxing a suspension of (2S)-2-amino-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl}propanoic acid (preparation given) and benzoylacetone in MeOH and trimethylorthoformate afforded 43% (2S)-(Z)-I [R1 = H; R2 = Me; R3 = Ph; R4 = Ph; R5 = H; R6 = Me; X = O; n = 2] which showed 39% glucose reduction in rats.

IT **258346-14-4P 258346-31-5P 258346-32-6P**
258346-33-7P 258346-34-8P 258346-35-9P
258346-36-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted oxazoles and thiazoles as hPPAR gamma and hPPAR alpha activators)

RN 258346-14-4 CAPLUS
CN L-Tyrosine, N-[(1Z)-1-methyl-3-oxo-3-phenyl-1-propenyl]-O-[(5-methyl-2-phenyl-4-oxazolyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 258346-31-5 CAPLUS
CN L-Tyrosine, O-[(5-ethyl-2-phenyl-4-oxazolyl)methyl]-N-[(1Z)-3-oxo-3-phenyl-1-(trifluoromethyl)-1-propenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 258346-32-6 CAPLUS
CN L-Tyrosine, O-[[5-ethyl-2-(4-fluorophenyl)-4-oxazolyl]methyl]-N-[(1Z)-3-oxo-3-phenyl-1-(trifluoromethyl)-1-propenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 258346-33-7 CAPLUS
CN L-Tyrosine, N-[(1Z)-1-ethyl-3-oxo-3-[4-(trifluoromethyl)phenyl]-1-propenyl]-O-[(5-ethyl-2-phenyl-4-oxazolyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 258346-34-8 CAPLUS
CN L-Tyrosine, O-[[5-ethyl-2-(4-fluorophenyl)-4-oxazolyl]methyl]-N-[(1Z)-1-ethyl-3-oxo-3-[4-(trifluoromethyl)phenyl]-1-propenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 258346-35-9 CAPLUS
CN L-Tyrosine, O-[(5-ethyl-2-phenyl-4-oxazolyl)methyl]-N-[(1Z)-1-methyl-3-oxo-3-[4-(trifluoromethyl)phenyl]-1-propenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 258346-36-0 CAPLUS
CN L-Tyrosine, O-[[5-ethyl-2-(4-fluorophenyl)-4-oxazolyl]methyl]-N-[(1Z)-1-methyl-3-oxo-3-[4-(trifluoromethyl)phenyl]-1-propenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



IT **258346-92-8P 258347-07-8P 258347-08-9P**
258347-11-4P 258347-12-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted oxazoles and thiazoles as hPPAR gamma and hPPAR alpha activators)

RN 258346-92-8 CAPLUS

CN L-Tyrosine, O-[(5-methyl-2-phenyl-4-oxazolyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 258347-07-8 CAPLUS

CN L-Tyrosine, O-[(5-ethyl-2-phenyl-4-oxazolyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 258347-08-9 CAPLUS

CN L-Tyrosine, N-[(1,1-dimethylethoxy)carbonyl]-O-[(5-ethyl-2-phenyl-4-oxazolyl)methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 258347-11-4 CAPLUS
CN L-Tyrosine, O-[[5-ethyl-2-(4-fluorophenyl)-4-oxazolyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 258347-12-5 CAPLUS
CN L-Tyrosine, N-[(1,1-dimethylethoxy)carbonyl]-O-[[5-ethyl-2-(4-fluorophenyl)-4-oxazolyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 8 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:736671 CAPLUS
DOCUMENT NUMBER: 131:351319
TITLE: Oxazolylmethoxybenzyl oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity
INVENTOR(S): Momose, Yu; Odaka, Hiroyuki; Imoto, Hiroshi; Kimura,

```
                              Hiroyuki; Sakamoto, Junichi
PATENT ASSIGNEE(S):           Takeda Chemical Industries, Ltd., Japan
SOURCE:                       PCT Int. Appl., 148 pp.
                              CODEN: PIXXD2
DOCUMENT TYPE:                Patent
LANGUAGE:                     English
FAMILY ACC. NUM. COUNT:       1
PATENT INFORMATION:

    PATENT NO.        KIND  DATE           APPLICATION NO.   DATE
    ---------------   ----  --------       ---------------   --------
    WO 9958510         A1   19991118       WO 1999-JP2407    19990510 <--
        W:  AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD,
            GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV,
            MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM,
            TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
        RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
            ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
            CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
    AU 9936297         A1   19991129       AU 1999-36297     19990510 <--
    AU 766831          B2   20031023
    BR 9910371         A    20010109       BR 1999-10371     19990510 <--
    EP 1077957         A1   20010228       EP 1999-918355    19990510 <--
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, FI
    TR 200003299       T2   20010521       TR 2000-20000329919990510 <--
    NZ 508066          A    20030328       NZ 1999-508066    19990510
    RU 2213738         C2   20031010       RU 2000-131183    19990510
    JP 2000034266      A2   20000202       JP 1999-130543    19990511 <--
    JP 3074532         B2   20000807
    JP 2000198772      A2   20000718       JP 1999-373202    19990511 <--
    US 6251926         B1   20010626       US 1999-423854    19991115 <--
    ZA 2000006121      A    20010518       ZA 2000-6121      20001030 <--
    LV 12606           B    20010520       LV 2000-148       20001101 <--
    NO 2000005531      A    20010105       NO 2000-5531      20001102 <--
    US 6495581         B1   20021217       US 2000-714699    20001116 <--
    US 2003186985      A1   20031002       US 2002-331056    20021227 <--
PRIORITY APPLN. INFO.:                  JP 1998-127921    A  19980511
                                        JP 1998-127922    A  19980511
                                        WO 1999-JP2407    W  19990510
                                        JP 1999-130543    A3 19990511
                                        US 1999-423854    A3 19991115
                                        US 2000-714699    A3 20001116
OTHER SOURCE(S):              MARPAT 131:351319
GI
```



I



II

AB Title compds. (I) [where R1 = (un)substituted hydrocarbon or heterocyclic group; X = bond, CO, CH(OH), or (alkyl)amino; n = 1-3; Y = O, S, SO, SO2, or (alkyl)amino; ring A = optionally substituted with 1-3 substituents; p = 1-8; R2 = H or (un)substituted hydrocarbon or heterocyclic group; q = 0-6; m = 0 or 1; R3 = OH, alkoxy, or (un)substituted NH2; R4 and R5 = independently H, hydrocarbon, or may form a ring with R2] were prepared for the prevention or treatment of diabetes mellitus, hyperlipemia, insulin insensitivity, insulin resistance, and impaired glucose tolerance. **Thus**, reaction of Me (E)-4-hydroxyimino-4-phenylbutyrate (preparation given) with 4-(4-chloromethylphenoxymethyl)-5-methyl-2-phenyloxazole (preparation given) in DMF followed by deesterification yielded (E)-II (60%). Representative compds. including II were mixed with a powdery diet and fed freely to KKAy mice for 4 days. Anal. of blood samples revealed 36% to 54% hypoglycemic action and 35% to 82% hypotriglyceridemic action of the treatment group compared to control animals. Compds. of the invention also exhibited excellent PPARγ-RXRα heterodimer ligand activity with EC50 values ranging from 0.024 μM to 0.79 μM.

IT **166253-46-9P 174258-31-2P 174258-32-3P**
250602-52-9P 250602-53-0P 250602-81-4P
250602-85-8P 250602-86-9P 250602-87-0P
250602-90-5P 250602-91-6P 250602-97-2P
250602-98-3P 250602-99-4P 250603-00-0P
250603-01-1P 250603-02-2P 250603-03-3P
250603-04-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of oxazolylmethoxybenzyl oxyiminoalkanoic acid derivs. with hypoglycemic and hypolipidemic activity for treatment of diabetes mellitus and related conditions)

RN 166253-46-9 CAPLUS

CN Benzenepropanol, 4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]- (9CI) (CA INDEX NAME)



RN 174258-31-2 CAPLUS
CN Benzenemethanol, 3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]- (9CI) (CA INDEX NAME)



RN 174258-32-3 CAPLUS
CN Oxazole, 4-[[3-(chloromethyl)phenoxy]methyl]-5-methyl-2-phenyl- (9CI) (CA INDEX NAME)



RN 250602-52-9 CAPLUS
CN Benzenemethanol, 4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]- (9CI) (CA INDEX NAME)



RN 250602-53-0 CAPLUS
CN Oxazole, 4-[[4-(chloromethyl)phenoxy]methyl]-5-methyl-2-phenyl- (9CI) (CA INDEX NAME)



RN 250602-81-4 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 250602-85-8 CAPLUS
CN Oxazole, 4-[[4-[(aminooxy)methyl]phenoxy]methyl]-5-methyl-2-phenyl- (9CI) (CA INDEX NAME)



RN 250602-86-9 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 250602-87-0 CAPLUS
CN Oxazole, 4-[[3-[(aminooxy)methyl]phenoxy]methyl]-5-methyl-2-phenyl- (9CI) (CA INDEX NAME)



RN 250602-90-5 CAPLUS
CN Benzeneacetic acid, 4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 250602-91-6 CAPLUS
CN Benzeneacetic acid, 4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]- (9CI) (CA INDEX NAME)



RN 250602-97-2 CAPLUS
CN Benzenemethanol, 2-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]- (9CI) (CA INDEX NAME)



RN 250602-98-3 CAPLUS
CN Oxazole, 4-[[2-(chloromethyl)phenoxy]methyl]-5-methyl-2-phenyl- (9CI) (CA INDEX NAME)



RN 250602-99-4 CAPLUS
CN Benzenemethanol, 3,5-dimethoxy-4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]- (9CI) (CA INDEX NAME)



RN 250603-00-0 CAPLUS
CN Oxazole, 4-[[4-(chloromethyl)-2,6-dimethoxyphenoxy]methyl]-5-methyl-2-phenyl- (9CI) (CA INDEX NAME)



RN 250603-01-1 CAPLUS
CN Benzenemethanol, 4-[[2-(2-furanyl)-5-methyl-4-oxazolyl]methoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 250603-02-2 CAPLUS
CN Oxazole, 4-[[4-(chloromethyl)-2-methoxyphenoxy]methyl]-2-(2-furanyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 250603-03-3 CAPLUS
CN Benzenemethanol, 3-methoxy-4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]- (9CI) (CA INDEX NAME)



RN 250603-04-4 CAPLUS
CN Oxazole, 4-[[4-(chloromethyl)-2-methoxyphenoxy]methyl]-5-methyl-2-phenyl- (9CI) (CA INDEX NAME)



IT **103789-66-8 159017-85-3 178239-24-2**
178610-35-0 250603-08-8 250603-09-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of oxazolylmethoxybenzyl oxyiminoalkanoic acid derivs. with hypoglycemic and hypolipidemic activity for treatment of diabetes mellitus and related conditions)
RN 103789-66-8 CAPLUS
CN Benzaldehyde, 4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]- (9CI) (CA INDEX NAME)



RN 159017-85-3 CAPLUS
CN Benzaldehyde, 3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]- (9CI) (CA INDEX NAME)



RN 178239-24-2 CAPLUS
CN Benzaldehyde, 4-[[2-(2-furanyl)-5-methyl-4-oxazolyl]methoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 178610-35-0 CAPLUS
CN Benzaldehyde, 3-methoxy-4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]- (9CI) (CA INDEX NAME)



RN 250603-08-8 CAPLUS
CN Benzaldehyde, 2-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]- (9CI) (CA INDEX NAME)



RN 250603-09-9 CAPLUS
CN Benzaldehyde, 3,5-dimethoxy-4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]- (9CI) (CA INDEX NAME)



IT **250601-04-8P 250601-16-2P 250601-17-3P**
250601-18-4P 250601-19-5P 250601-20-8P
250601-29-7P 250601-30-0P 250601-37-7P
250601-39-9P 250601-40-2P 250601-44-6P
250601-50-4P 250601-56-0P 250601-57-1P
250601-62-8P 250601-64-0P 250601-65-1P
250601-66-2P 250601-68-4P 250601-74-2P
250601-77-5P 250601-78-6P 250601-82-2P
250601-91-3P 250601-92-4P 250601-94-6P
250601-99-1P 250602-09-6P 250602-10-9P
250602-17-6P 250602-19-8P 250602-21-2P

250602-22-3P 250602-23-4P 250602-32-5P
250602-41-6P 250602-48-3P 250602-50-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(target compound; preparation of oxazolylmethoxybenzyl oxyiminoalkanoic acid derivs. with hypoglycemic and hypolipidemic activity for treatment of diabetes mellitus and related conditions)

RN 250601-04-8 CAPLUS

CN Benzenebutanoic acid, γ-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, (γE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-16-2 CAPLUS

CN Benzeneacetic acid, 4-methoxy-α-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, ethyl ester, (αZ)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-17-3 CAPLUS

CN Butanoic acid, 3-methyl-2-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, ethyl ester, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-18-4 CAPLUS
CN Butanoic acid, 3-methyl-2-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, ethyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-19-5 CAPLUS
CN Benzeneacetic acid, 4-bromo-α-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, ethyl ester, (αE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-20-8 CAPLUS
CN Benzeneacetic acid, 4-bromo-α-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, ethyl ester, (αZ)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-29-7 CAPLUS
CN 3-Pyridineacetic acid, α-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, ethyl ester, (αZ)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-30-0 CAPLUS
CN 3-Pyridineacetic acid, α-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, ethyl ester, (αE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-37-7 CAPLUS
CN Benzeneacetic acid, 3-benzoyl-α-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, ethyl ester, (αZ)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-39-9 CAPLUS
CN Benzeneacetic acid, α-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-3-(1-phenylethenyl)-, ethyl ester, (αZ)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-40-2 CAPLUS
CN Benzeneacetic acid, α-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-3-[(1E)-2-phenylethenyl]-, ethyl ester, (αZ)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-44-6 CAPLUS
CN Benzenebutanoic acid, γ-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-4-phenoxy-, ethyl ester, (γE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-50-4 CAPLUS
CN Benzenepropanoic acid, β-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, ethyl ester, (βE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-56-0 CAPLUS
CN Benzenehexanoic acid, ε-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, ethyl ester, (εE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-57-1 CAPLUS
CN Benzenehexanoic acid, ε-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, ethyl ester, (εZ)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-62-8 CAPLUS
CN 2-Pyridinebutanoic acid, γ-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, ethyl ester, (γE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-64-0 CAPLUS
CN 2-Furanbutanoic acid, γ-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, ethyl ester, (γE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-65-1 CAPLUS
CN 2-Furanbutanoic acid, γ-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, ethyl ester, (γZ)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-66-2 CAPLUS
CN 3-Pyridinebutanoic acid, γ-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 250601-68-4 CAPLUS
CN 4-Pyridinebutanoic acid, γ-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 250601-74-2 CAPLUS
CN Benzenehexanoic acid, ε-[[[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, ethyl ester, (εE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-77-5 CAPLUS
CN Benzeneheptanoic acid, ζ-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, ethyl ester, (ζE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-78-6 CAPLUS
CN Benzeneoctanoic acid, η-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, ethyl ester, (ηE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-82-2 CAPLUS
CN Benzeneoctanoic acid, η-[[[4-[[2-(2-furanyl)-5-methyl-4-oxazolyl]methoxy]phenyl]methoxy]imino]-, ethyl ester, (ηE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-91-3 CAPLUS
CN Benzenebutanoic acid, γ-[[[4-[[2-(2-furanyl)-5-methyl-4-oxazolyl]methoxy]phenyl]methoxy]imino]-, methyl ester, (γE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-92-4 CAPLUS
CN Benzenebutanoic acid, γ-[[[4-[[5-methyl-2-(2-thienyl)-4-oxazolyl]methoxy]phenyl]methoxy]imino]-, methyl ester, (γE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-94-6 CAPLUS
CN Benzeneoctanoic acid, η-[[[4-[[5-methyl-2-(2-thienyl)-4-oxazolyl]methoxy]phenyl]methoxy]imino]-, ethyl ester, (ηE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-99-1 CAPLUS
CN Benzenebutanoic acid, γ-[[[4-[(2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, methyl ester, (γE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250602-09-6 CAPLUS
CN Benzenepropanoic acid, α,α-dimethyl-β-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, ethyl ester, (βZ)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250602-10-9 CAPLUS
CN Benzenepropanoic acid, α,α-dimethyl-β-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, (βZ)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250602-17-6 CAPLUS
CN Benzeneoctanoic acid, 4-methoxy-η-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, methyl ester, (ηE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250602-19-8 CAPLUS
CN Benzeneoctanoic acid, 4-chloro-η-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, methyl ester, (ηE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250602-21-2 CAPLUS
CN Benzeneoctanoic acid, 4-chloro-η-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, methyl ester, (ηZ)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250602-22-3 CAPLUS

CN Benzeneoctanoic acid, 4-fluoro-η-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, methyl ester, (ηE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250602-23-4 CAPLUS

CN Benzeneoctanoic acid, 4-fluoro-η-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, methyl ester, (ηZ)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250602-32-5 CAPLUS
CN Benzenehexanoic acid, ε-[[[4-[[2-(2-furanyl)-5-methyl-4-oxazolyl]methoxy]phenyl]methoxy]imino]-, ethyl ester, (εE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250602-41-6 CAPLUS
CN Benzenehexanoic acid, α,α-dimethyl-ε-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, methyl ester, (εE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250602-48-3 CAPLUS
CN Benzenebutanoic acid, γ-[[[4-[[2-(2-furanyl)-5-methyl-4-oxazolyl]methoxy]-3-methoxyphenyl]methoxy]imino]-, methyl ester, (γE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250602-50-7 CAPLUS
CN Benzenebutanoic acid, γ-[[[3-methoxy-4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, methyl ester, (γE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **250600-98-7P 250600-99-8P 250601-02-6P**
250601-03-7P 250601-05-9P 250601-06-0P
250601-07-1P 250601-08-2P 250601-09-3P
250601-10-6P 250601-11-7P 250601-12-8P
250601-13-9P 250601-14-0P 250601-15-1P
250601-21-9P 250601-22-0P 250601-23-1P
250601-24-2P 250601-25-3P 250601-26-4P
250601-27-5P 250601-28-6P 250601-31-1P
250601-32-2P 250601-34-4P 250601-35-5P
250601-36-6P 250601-38-8P 250601-41-3P
250601-42-4P 250601-43-5P 250601-45-7P
250601-51-5P 250601-58-2P 250601-60-6P
250601-61-7P 250601-63-9P 250601-67-3P
250601-69-5P 250601-70-8P 250601-71-9P
250601-72-0P 250601-73-1P 250601-75-3P
250601-76-4P 250601-79-7P 250601-80-0P
250601-81-1P 250601-83-3P 250601-84-4P
250601-93-5P 250601-96-8P 250602-01-8P
250602-05-2P 250602-07-4P 250602-11-0P
250602-12-1P 250602-13-2P 250602-14-3P
250602-15-4P 250602-16-5P 250602-18-7P
250602-24-5P 250602-25-6P 250602-26-7P
250602-27-8P 250602-30-3P 250602-31-4P
250602-33-6P 250602-34-7P 250602-36-9P
250602-40-5P 250602-42-7P 250602-43-8P
250602-44-9P 250602-45-0P 250602-46-1P
250602-47-2P 250602-49-4P 250602-51-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compound; preparation of oxazolylmethoxybenzyl oxyiminoalkanoic acid derivs. with hypoglycemic and hypolipidemic activity for treatment of diabetes mellitus and related conditions)

RN 250600-98-7 CAPLUS

CN Benzeneacetic acid, α-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, (αZ)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250600-99-8 CAPLUS
CN Benzeneacetic acid, α-[[3-[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]propoxy]imino]-, (αZ)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-02-6 CAPLUS
CN Benzeneacetic acid, α-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, (αE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-03-7 CAPLUS
CN Benzenepropanoic acid, α-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, (αE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-05-9 CAPLUS

CN Hexanoic acid, 2-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-06-0 CAPLUS

CN Propanoic acid, 2-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-07-1 CAPLUS

CN Benzeneacetic acid, 4-bromo-α-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, (αZ)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-08-2 CAPLUS
CN Benzeneacetic acid, α-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-4-phenoxy-, (αZ)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-09-3 CAPLUS
CN Benzeneacetic acid, α-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-4-phenoxy-, (αE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-10-6 CAPLUS
CN Benzeneacetic acid, α-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-3-phenoxy-, (αZ)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-11-7 CAPLUS
CN Benzeneacetic acid, α-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-3-phenoxy-, (αE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-12-8 CAPLUS
CN Benzeneacetic acid, 4-fluoro-α-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, (αZ)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-13-9 CAPLUS
CN Benzeneacetic acid, 4-fluoro-α-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, (αE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-14-0 CAPLUS
CN Benzenebutanoic acid, 4-fluoro-γ-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, (γE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-15-1 CAPLUS
CN Benzenepentanoic acid, δ-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, (δE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-21-9 CAPLUS
CN Benzeneacetic acid, 4-methoxy-α-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, (αZ)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-22-0 CAPLUS
CN Butanoic acid, 3-methyl-2-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-23-1 CAPLUS
CN Butanoic acid, 3-methyl-2-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-24-2 CAPLUS
CN Benzeneacetic acid, 4-bromo-α-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, (αE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-25-3 CAPLUS
CN [1,1'-Biphenyl]-4-acetic acid, α-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, (αE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-26-4 CAPLUS
CN [1,1'-Biphenyl]-4-acetic acid, α-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, (αZ)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-27-5 CAPLUS
CN Benzeneacetic acid, α-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-4-(3-thienyl)-, (αZ)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-28-6 CAPLUS
CN Benzeneacetic acid, α-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-4-[(1E)-2-phenylethenyl]-, (αZ)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-31-1 CAPLUS
CN 3-Pyridineacetic acid, α-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, 1-oxide, (αZ)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-32-2 CAPLUS
CN 3-Pyridineacetic acid, α-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, (αZ)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-34-4 CAPLUS
CN 3-Pyridineacetic acid, α-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, 1-oxide, (αE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-35-5 CAPLUS
CN 3-Pyridineacetic acid, α-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, (αE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-36-6 CAPLUS
CN Benzeneacetic acid, 3-bromo-α-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, ethyl ester, (αZ)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-38-8 CAPLUS
CN Benzeneacetic acid, 3-benzoyl-α-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, (αZ)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-41-3 CAPLUS
CN Benzeneacetic acid, 3-bromo-α-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, (αZ)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-42-4 CAPLUS
CN Benzeneacetic acid, α-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-3-(1-phenylethenyl)-, (αZ)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN   250601-43-5   CAPLUS
CN   Benzeneacetic acid, α-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-3-[(1E)-2-phenylethenyl]-, (αZ)- (9CI)   (CA INDEX NAME)

Double bond geometry as shown.



RN   250601-45-7   CAPLUS
CN   Benzenebutanoic acid, γ-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-4-phenoxy-, (γE)- (9CI)   (CA INDEX NAME)

Double bond geometry as shown.



RN   250601-51-5   CAPLUS
CN   Benzenepropanoic acid, β-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, (βE)- (9CI)   (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-58-2 CAPLUS
CN Benzenehexanoic acid, ε-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, (εE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-60-6 CAPLUS
CN Benzenehexanoic acid, ε-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, (εZ)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-61-7 CAPLUS
CN 1H-Indene-1-carboxylic acid, 2,3-dihydro-3-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, (3E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-63-9 CAPLUS
CN 2-Pyridinebutanoic acid, γ-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, (γE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-67-3 CAPLUS
CN 2-Furanbutanoic acid, γ-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, (γZ)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-69-5 CAPLUS
CN 3-Pyridinebutanoic acid, γ-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, (γE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-70-8 CAPLUS
CN 4-Pyridinebutanoic acid, γ-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, (γE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-71-9 CAPLUS
CN 2-Furanbutanoic acid, γ-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, (γE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-72-0 CAPLUS
CN Benzenenonanoic acid, θ-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, (θE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-73-1 CAPLUS

CN Benzenebutanoic acid, γ-[[[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, methyl ester, (γE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-75-3 CAPLUS

CN Benzenehexanoic acid, ε-[[[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, (εE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-76-4 CAPLUS

CN Benzenebutanoic acid, γ-[[[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, (γE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-79-7 CAPLUS
CN Benzeneoctanoic acid, η-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, ethyl ester, (ηZ)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-80-0 CAPLUS
CN Benzeneoctanoic acid, η-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, (ηE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-81-1 CAPLUS
CN Benzenehexanamide, ε-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, (εE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-83-3 CAPLUS

CN Benzenebutanoic acid, γ-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, methyl ester, (γE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-84-4 CAPLUS

CN Benzenebutanoic acid, γ-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, methyl ester, (γZ)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-93-5 CAPLUS

CN Benzenebutanoic acid, γ-[[[4-[[2-(2-furanyl)-5-methyl-4-oxazolyl]methoxy]phenyl]methoxy]imino]-, (γE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250601-96-8 CAPLUS
CN Benzenebutanoic acid, γ-[[[4-[[5-methyl-2-(2-thienyl)-4-oxazolyl]methoxy]phenyl]methoxy]imino]-, (γE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250602-01-8 CAPLUS
CN Benzenebutanoic acid, γ-[[[4-[(2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, (γE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250602-05-2 CAPLUS
CN Benzenebutanamide, γ-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, (γE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250602-07-4 CAPLUS
CN Benzenebutanoic acid, γ-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, sodium salt, (γE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250602-11-0 CAPLUS
CN Benzenepropanamide, β-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, (βE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250602-12-1 CAPLUS
CN Benzenebutanamide, N,N-dimethyl-γ-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, (γE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250602-13-2 CAPLUS
CN Benzenebutanamide, N-methyl-γ-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, (γE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250602-14-3 CAPLUS
CN Benzenebutanoic acid, γ-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, lithium salt, (γE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250602-15-4 CAPLUS
CN Benzeneheptanoic acid, ζ-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, (ζE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250602-16-5 CAPLUS
CN Benzeneoctanoic acid, η-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, (ηZ)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250602-18-7 CAPLUS
CN Benzeneoctanoic acid, 4-methoxy-η-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, (ηE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250602-24-5 CAPLUS
CN Benzeneoctanoic acid, 4-chloro-η-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, (ηE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250602-25-6 CAPLUS

CN Benzeneoctanoic acid, 4-chloro-η-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, (ηZ)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250602-26-7 CAPLUS

CN Benzeneoctanoic acid, 4-fluoro-η-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, (ηE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250602-27-8 CAPLUS

CN Benzeneoctanoic acid, 4-fluoro-η-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, (ηZ)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250602-30-3 CAPLUS
CN Benzeneoctanoic acid, η-[[[4-[[2-(2-furanyl)-5-methyl-4-oxazolyl]methoxy]phenyl]methoxy]imino]-, (ηE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250602-31-4 CAPLUS
CN Benzeneoctanoic acid, η-[[[4-[[5-methyl-2-(2-thienyl)-4-oxazolyl]methoxy]phenyl]methoxy]imino]-, (ηE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250602-33-6 CAPLUS
CN Benzenehexanoic acid, ε-[[[4-[[2-(2-furanyl)-5-methyl-4-oxazolyl]methoxy]phenyl]methoxy]imino]-, (εE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250602-34-7 CAPLUS
CN Benzenehexanoic acid, ε-[[[4-[[5-methyl-2-(2-thienyl)-4-oxazolyl]methoxy]phenyl]methoxy]imino]-, ethyl ester, (εE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250602-36-9 CAPLUS
CN Benzenehexanoic acid, ε-[[[4-[[5-methyl-2-(2-thienyl)-4-oxazolyl]methoxy]phenyl]methoxy]imino]-, (εE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250602-40-5 CAPLUS
CN Benzenebutanamide, γ-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, (γZ)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250602-42-7 CAPLUS
CN Benzenehexanoic acid, α,α-dimethyl-ε-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, (εE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250602-43-8 CAPLUS
CN Benzenehexanamide, ε-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-N-(methylsulfonyl)-, (εE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250602-44-9 CAPLUS
CN Benzenebutanoic acid, γ-[[[2-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, methyl ester, (γE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250602-45-0 CAPLUS
CN Benzenebutanoic acid, γ-[[[2-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, (γE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250602-46-1 CAPLUS
CN Benzenebutanoic acid, γ-[[[3,5-dimethoxy-4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, methyl ester, (γE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250602-47-2 CAPLUS
CN Benzenebutanoic acid, γ-[[[3,5-dimethoxy-4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, (γE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250602-49-4 CAPLUS

CN Benzenebutanoic acid, γ-[[[4-[[2-(2-furanyl)-5-methyl-4-oxazolyl]methoxy]-3-methoxyphenyl]methoxy]imino]-, (γE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 250602-51-8 CAPLUS

CN Benzenebutanoic acid, γ-[[[3-methoxy-4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]imino]-, (γE)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 9 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:	1999:172591 CAPLUS
DOCUMENT NUMBER:	130:209698
TITLE:	Preparation of aryloxazoles and analogs as analgesics
INVENTOR(S):	Panetta, Jill Ann; Shannon, Harlan Edgar
PATENT ASSIGNEE(S):	Eli Lilly and Company, USA
SOURCE:	PCT Int. Appl., 144 pp. CODEN: PIXXD2
DOCUMENT TYPE:	**Patent**

```
LANGUAGE:                   English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.        KIND  DATE          APPLICATION NO.   DATE
     ---------------   ----  --------      ---------------   --------
     WO 9909980         A1   19990304      WO 1998-US17667   19980826 <--
         W:  AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH,
             GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
             LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG,
             SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, BF, BJ, CF, CG, CI, CM, GA,
             GN, GW, ML, MR, NE, SN, TD, TG
     US 5942530         A    19990824      US 1998-138495    19980824 <--
     CA 2302504         AA   19990304      CA 1998-2302504   19980826 <--
     AU 9890354         A1   19990316      AU 1998-90354     19980826 <--
     EP 908186          A2   19990414      EP 1998-306807    19980826 <--
     EP 908186          A3   19990421
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO
     JP 2001513557      T2   20010904      JP 2000-507370    19980826 <--
PRIORITY APPLN. INFO.:                  US 1997-57389P    P  19970828
                                        WO 1998-US17667   W  19980826
OTHER SOURCE(S):            MARPAT 130:209698
```

GI



I

AB Title compds. [I; R1 = (CH2)mCHR4Z1Z2R6; R2 = ROZ3; R,R3 = H or alkyl; R6 = CO(CH2)nNR7R8, Z4NR7R8, etc.; R7,R8 = H, (hydroxy)alkyl, piperidinylalkyl; NR7R8 = heterocyclyl; Z = O or S; Z1 = CHR5, O, S; R5 = H; R4R5 = bond; Z2 = phenylene, pyridinediyl, etc.; Z3 = 2,6-dialkyl-1,4-phenylene; Z4 = alkylene; m = 0 or 1; n = 0-4] were prepared as analgesics (no data). **Thus**, 3,5-di-tert-butyl-4-hydroxybenzamide was cyclocondensed with ClCH2COCH2CO2Et and the reduced product etherified by 4-(HO)C6H4CHO to give I (R1 = CH2CH2OC6H4R6-4, R2 = 3,5-di-tert-butyl-4-hydroxyphenyl, R3 = H)(II; R6 = CHO) which was reductively aminated by EtNH2 to give II (R6 = CH2NHEt).

IT **206122-46-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aryloxazoles and analogs as analgesics)

RN 206122-46-5 CAPLUS

CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-[4-[[4-[(ethylmethylamino)methyl]phenoxy]methyl]-2-oxazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT 	**220892-13-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of aryloxazoles and analogs as analgesics)
RN 220892-13-7 CAPLUS
CN Benzaldehyde, 2-[[2-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-4-oxazolyl]methoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 10 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:172590 CAPLUS
DOCUMENT NUMBER: 130:209697
TITLE: Preparation of aryloxazoles and analogs for treatment of neuralgia
INVENTOR(S): Panetta, Jill Ann; Shannon, Harlan Edgar
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 133 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

```
     PATENT NO.        KIND  DATE          APPLICATION NO.   DATE
     ---------------   ----  --------      ---------------   --------
     WO 9909979         A1   19990304      WO 1998-US17666   19980826 <--
         W:  AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH,
             GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
             LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG,
             SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, BF, BJ, CF, CG, CI, CM, GA,
             GN, GW, ML, MR, NE, SN, TD, TG
     US 5952360         A    19990914      US 1998-138626    19980824 <--
     CA 2302442        AA    19990304      CA 1998-2302442   19980826 <--
     AU 9889207        A1    19990316      AU 1998-89207     19980826 <--
     EP 906755         A2    19990407      EP 1998-306806    19980826 <--
     EP 906755         A3    19990421
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO
     JP 2001513556     T2    20010904      JP 2000-507369    19980826 <--
PRIORITY APPLN. INFO.:                  US 1997-57165P  P  19970828
                                        WO 1998-US17666 W  19980826
OTHER SOURCE(S):          MARPAT 130:209697
GI
```



AB Title compds. [I; R1 = (CH2)mCHR4Z1Z2R6; R2 = ROZ3; R,R3 = H or alkyl; R6 = CO(CH2)nNR7R8, Z4NR7R8, etc.; R7,R8 = H, (hydroxy)alkyl, piperidinylalkyl; NR7R8 = heterocyclyl; Z = O or S; Z1 = CHR5, O, S; R5 = H; R4R5 = bond; Z2 = phenylene, pyridinediyl, etc.; Z3 = 2,6-dialkyl-1,4-phenylene; Z4 = alkylene; m = 0 or 1; n = 0-4] were prepared as analgesics (no data). **Thus**, 3,5-di-tert-butyl-4-hydroxybenzamide was cyclocondensed with ClCH2COCH2CO2Et and the reduced product etherified by 4-(HO)C6H4CHO to give I (R1 = CH2CH2OC6H4R6-4, R2 = 3,5-di-tert-butyl-4-hydroxyphenyl, R3 = H)(II; R6 = CHO) which was reductively aminated by EtNH2 to give II (R6 = CH2NHEt).

IT **206122-46-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aryloxazoles and analogs for treatment of neuralgia)

RN 206122-46-5 CAPLUS

CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-[4-[[4-[(ethylmethylamino)methyl]phenoxy]methyl]-2-oxazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



IT **220892-13-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of aryloxazoles and analogs for treatment of neuralgia)

RN 220892-13-7 CAPLUS

```
CN   Benzaldehyde, 2-[[2-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-4-
     oxazolyl]methoxy]- (9CI)  (CA INDEX NAME)
```



```
REFERENCE COUNT:           4      THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
                                  RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> log y
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                        57.46     859.82

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)            SINCE FILE      TOTAL
                                                           ENTRY    SESSION
CA SUBSCRIBER PRICE                                        -6.93      -9.70

STN INTERNATIONAL LOGOFF AT 12:27:10 ON 25 MAY 2004
```